Browse Month: November 2017

An Essential Overview of the Pharmaceutical Industry #pharma #business

#pharmaceutical industry overview


An Essential Overview of the Pharmaceutical Industry

Course overview

This programme will give you an invaluable overview of the Pharmaceutical industry, from discovery of the molecule through development to marketing. It will provide a step by step understanding of the main areas of drug development and will discuss the roles and responsibilities of key staff involved. You will be given a comprehensive glossary of the most commonly used industry terms which will be an invaluable reference to help you get to grips with the technical terminology and jargon.

Who should attend

All those wanting to achieve a better understanding of how the Pharmaceutical Industry works. The course will be particularly helpful for those wanting to understand what other departments do, for new staff working in the industry and for non-scientific and administrative personnel.

Why you should attend

  • Increase your understanding of the Pharma industry
  • Develop your knowledge of the stages of drug development from dug discovery through to marketing
  • Get to grips with the phases of Clinical Trials, Regulatory Processes and Pharmacovigilance Requirements
  • Understand the role and responsibilities of key department and how they work together
  • Demystify the technical terminology and jargon


How are drugs developed?

  • Overview of drug development and why we patent drugs
  • Drug discovery how to identify
  • New Chemical Entities ( NCE )
  • Non-clinical / pre-clinical development of lead compounds

Demystifying the jargon and terminology in the pharma industry

What are the roles and responsibilities of the people in the pharmaceutical industry?

Clinical trials and how they advance a drug to market

  • What happens at each phase of clinical research?
  • Ensuring the quality of the data: monitoring, auditing and working to ICH


  • What is safety reporting, signal detection, evaluation and risk management?

Regulatory processes

  • Overview of regulatory submission and approval procedures
  • Understanding the ICH process
  • The electronic Common Technical Document (eCTD), and the impact of the EU Clinical Trial Regulation

Potential impact of Brexit to the pharma industry

  • How are drugs marketed and sold?

Expert speaker

Dr Laura Brown is an independent QA and Training Consultant and Director of the MSc in Clinical Research, School of Pharmacy at the University of Cardiff and Course Director of the MSc Regulatory Affairs, TOPRA. Laura has many years’ experience in the Pharmaceutical Industry. She has worked for several companies including Glaxo Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and Phoenix International. She has worked as a Clinical Research Manager, Audit Director and as Head of a Training Department.


Dr Laura Brown MBA. BSc (Biochemistry), BSc (Psychology), PhD, Diploma in Clinical Science, FICR. is a Pharmaceutical Management and Training Consultant, Course Director for the MSc in Clinical Research at the University of Cardiff, and MSc Regulatory Affairs, TOPRA. She has more than 19 years experience in the pharmaceutical industry and has worked for several companies, including GlaxoWellcome, Hoechst Marion Roussel, Farmitalia and Phoenix International. She has worked in Drug Development, Clinical Research, Quality Assurance and Marketing. She has a particular expertise in Clinical Research and GCP issues. She was Chairman of the ACRPI GCP Forum for six years. She regularly writes on clinical research issues and ICH GCP. is author of SCRIP’s GCP guide and is a member of the editorial board of the Board of the Good Clinical Practice Journal. She is co-author of several books on management including ‘Developing the Individual’, ‘The Ultimate Book of Business Skills’ and ‘Pharmaceutical Project Management’.

You may also be interested in.

Previous customers include.

  • (MHRA) Medicines & Healthcare Products Regulatory Agency
  • Abbott EPD
  • Abbott Products Operations AG
  • Actavis Plc
  • Allergan
  • Allergan UK Limited
  • Bayer
  • BD Pharmaceutical System
  • Becton Dickinson UK Ltd (Oxford)
  • Chiesi Farmaceutici SPA
  • Chugai Pharma UK Ltd
  • Debiopharm International SA
  • Digiweb Ltd
  • Eisai Limited
  • FFG-Austrian Research Promotion Agency
  • Janssen
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • MHRA
  • Monachem
  • Mundipharma Research Limited
  • Norgine
  • Pharmacovigilance Matters Limited
  • Pliva Croatia d.o.o.
  • Shire Pharmaceuticals
  • Sunovion Pharmaceuticals Europe
  • Teva Pharmaceuticals Ltd
  • Toxikon Europe NV
  • UCB Biopharma SPRL
  • UCB Pharma SA

The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide #future #of #pharmaceutical #industry

#top generic pharmaceutical companies


LONDON, July 25, 2016 /PRNewswire/ — Did you know?

– Zentiva, the generics business of the Sanofi Group, employs 6,000 people worldwide.

– Jeff Watson is President, Global Generics at Apotex, the largest Canadian-owned pharmaceutical company.

– Željko Dudi? is Director of Purchasing at Hemofarm, the leading generic pharmaceutical company in Serbia.

– Beximco Pharmaceuticals, a leading manufacturer and exporter of medicines in Bangladesh, currently produces more than 300 generic medicines which are available in well over 500 different presentations.

– South African-based Aspen is ranked as the ninth largest generic company in the world.

– Fresenius Kabi offers a broad range of intravenously administered generic drugs across a wide array of therapeutic categories: oncology drugs, anesthetics analgesics, anti-infectives, critical care drugs.

– Mumbai, India headquartered Sun Pharmaceutical’s consolidated revenues for the 12 months ending March 2015 are US$ 4.5 billion.

– Since June 2015, Madrid headquartered manufacturer of generic injectable drugs, Genéricos Españoles, has been owned by Altan, a private, specialty pharmaceutical company based in Ireland.

These are just a tiny sample of the 1,000’s of facts to be found in ‘The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide’.

There are many manufacturers of pharmaceuticals. This report profiles those with a focus on generics. These major companies have the experience, know-how and resources that enable them to identify patented products and make them available as a generic on the day of patent expiry. They manufacture multiple products in various dosage forms and in a wide variety of therapeutic classes and export them across the globe.

Profile information for each company in ‘The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide’ typically includes:

– Company Contact Information – Address, Telephone and Fax Numbers, Email and Website Address
– Key Company Decision Makers – From CEO and Main Board, to Key Senior Managers
– Specialised fields such as Company Description, Ownership, Products, Therapeutic Focus, Year Established, Number of Employees and Revenue.

Report Target Market:

1) Pharmaceutical Companies

Usage: competitive/financial analysis and strategic partner/alliance identification.

2) Suppliers
This report is perfect for suppliers of raw materials and equipment necessary for pharmaceutical production.

‘The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide’ is ideal for distributors of pharmaceuticals to identify all of the leading manufacturers with the best products and the widest ranges.

Note: Most people will be aware of some of the major manufacturers of generic pharmaceuticals such as Krka, Lupin and Par Pharmaceutical but this report looks at all 100 of the top companies – companies like – Polpharma – Founded over 80 years ago, Polpharma is among the top 20 generic drug manufacturers in the world. The Company employs more than 7,500 people in Poland and in international markets. Polpharma has 7 manufacturing plants in Poland, Russia and Kazakhstan and 7 research and development centres. Polpharma’s portfolio includes about 600 products and another 200 are being developed. The Company specialises in pharmaceutical preparations used in cardiology, gastroenterology and neurology. They actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia. Polpharma has sales of US$ 1 billion per year and is led by Maurice Chagnaud, CEO.

Report data field structure is as follows:

– Company Name
– Address
– Telephone
– Fax
– Email
– Website
– Year Established
– Number of Employees
– Key Executives
– Company Description
– Products
– Therapeutic Focus
– Revenue ($U.S. million)
– Ownership
– Stock Exchange/Ticker Symbol
– Parent Company

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

Bio Pharma Logistics #phrma

#bi pharma


Bio Pharma Logistics

In compliance with cGxP requirements.

Specialists in cold chain logistics.

Expertise in clinical trials.

When your shipment matters.

Intelligent warehousing solutions.

Global deliveries, always on schedule.

Committed to the environment.

Bio Pharma Logistics – Video

Bio Pharma Logistics. When your shipment matters.

Our company is specialised in (bio) pharmaceutical shipments & clinical trials, warehousing and added-value services and has been a reference for many years in this niche market. For more than a decade we have been preferred supplier of many high-end (bio) pharma chemical companies. As an independent, ethical and multimodal company, with a worldwide network of agents, our customers can rely on our expertise, global reach and experience.

For more than 19 years, we have served our customers thanks to our well trained staff, high quality services and the ability to provide tailored, creative and competitive logistics solutions. All of our staff members, from drivers, to handlers, to administrative personnel and agents are trained to the specific needs of the pharmaceutical sector. Bio Pharma Logsitics is ISO 14001 & ISO 9001 certified and all of our procedures are in compliance with cGxP requirements.

Flexibility and responsiveness: that is what the fast-moving (bio)pharmaceutical, life sciences and chemical industry needs from its suppliers and that is exactly what Bio Pharma Logistics delivers!

Track Trace

You can trace your consignment via or be informed individually with an up-to-date and personalised Proof of Delivery.

Accreditations Certifications

Bio Pharma Logistics – HQ

Scientific Parc Louvain-la-Neuve
11 Rue Granbonpré
1348 Mont-Saint-Guibert

Legal Notice

General Proprietary Rights.
Limitation of Liability.
Compliance with Laws.
Notice of potential infraction.
General Terms and Conditions of carriage.

2016 Bio Pharma Logistics

2013 MDM Market Leaders: Top Pharmaceutical Distributors #top #pharmaceutical #companies

#pharmaceutical distribution companies


Editor’s note: This article was provided by Adam J. Fein, Ph.D. founder and president of Pembroke Consulting, Inc. and one of the country’s foremost experts on pharmaceutical economics and channel strategy. He also writes the writes the popular and influential Drug Channels website and publishes an annual report on the pharmaceutical wholesaling industry.

LATEST REPORT NOW AVAILABLE: Click here to download the 2013-2014 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Three companies generate about 85% of all revenues from drug distribution in the United States: AmerisourceBergen Corporation (NYSE:ABC). Cardinal Health, Inc. (NYSE:CAH). and McKesson Corporation (NYSE:MCK). In calendar year 2012, total revenues from the drug distribution divisions of these Big Three wholesalers were $289.8 billion, down slightly from 2011.

In addition to these three companies, there are a number of smaller companies. Here are some other large wholesalers and their estimated annual revenues:

  • Morris & Dickson ($3.6 billion)
  • H.D. Smith ($3.4 billion)
  • Smith Drug ($2.2 billion)
  • Curascript Specialty Distribution ($2.1 billion)
  • NC Mutual Wholesale Drug ($1.1 billion)
  • Anda Distribution ($1.0 billion)
  • Rochester Drug Cooperative ($825 million)

Additional regional and specialty wholesalers include: Burlington Drug, Dakota Drug, FFF Enterprises, Florida Infusion, Harvard Drug Group, King Drug, Metro Medical, Miami-Luken, Seacoast, and Value Drug. There are also thousands of very small companies that are licensed as wholesalers. Over the past 10 years, the Big Three companies have acquired many regional and specialty wholesalers. Notable acquisitions in the past few years include Cardinal Health’s acquisition of Kinray and DIK Drugs. and McKesson’s acquisition of US Oncology and PSS World Medical .

The industry includes two primary types of companies:

  • Full-line wholesalers purchase, inventory, and sell a manufacturer’s complete pharmaceutical product line unless otherwise designated. These wholesalers sell primarily to pharmacies outside a wholesaler’s ownership control. These wholesalers service a diverse set of outlets, although 74% of the drug wholesale industry’s revenues derives from sales to retail, mail, and specialty pharmacies.
  • Specialty distributors sell specialty pharmaceuticals primarily to physician-owned/operated clinics, hospitals, and hospital-owned outpatient clinics. Many specialty drugs sold via wholesale distribution channels usually require administration by a healthcare provider, such as a physician or nurse. Oncology products account for almost half of sales by specialty distributors.

The largest specialty distributors are divisions of full-line wholesalers. These include the distributors in AmerisourceBergen Corporation’s Specialty Group (Oncology Supply, ASD Healthcare, and Besse Medical) and McKesson Specialty (a business unit of McKesson Corporation). We estimate that these two companies generate about 75% of total specialty distributor revenues. Other large specialty distributors include CuraScript SD (owned by Express Scripts) and such independent specialty distributors as Metro Medical and Florida Infusion.

Pharmaceutical wholesalers are diversifying beyond traditional core product distribution services by offering new services to manufacturers, payers, and providers. For instance, AmerisourceBergen operates the largest service business providing manufacturers with reimbursement support, clinical support, and patient assistance programs for specialty pharmaceuticals. (See Why ABC Grabbed Caremark’s Reimbursement Hub .) Cardinal Health owns p1 Healthcare, which provides a variety of oncology-related services and products to physicians, payers, and manufacturers. McKesson is the country’s largest provider of health information technology products and services.

Four significant trends are affecting the drug wholesaling industry:

Pharmaceutical Market Growth and Healthcare Reform —U.S. healthcare reform will increase spending on drugs due to such factors as the healthcare coverage expansion and the shrinking Medicare Part D coverage gap. (See Who Will Pay for Prescription Drugs in 2021? ) Wholesalers will benefit from this projected growth. Over the next few years, revenues in the pharmaceutical industry will shift from traditional brand-name drugs to specialty drugs. (See More Drug Trend Forecasts: An Exclusive Look at Prime Therapeutics vs. the Big Two PBMs .) Specialty distributors will benefit from growth in specialty products administered in physician offices and clinics. Full-line wholesalers will benefit most from specialty drugs administered by healthcare providers in hospitals and from those dispensed by smaller pharmacies.

Consolidation and Changes in Pharmacy Industry Market Structure —The ongoing consolidation of the pharmacy industry will continue to pressure wholesaler profit margins from drug distribution. Independent drugstores are a crucial customer set for drug wholesalers, because they purchase almost all of their pharmaceutical needs from drug wholesalers. However, smaller pharmacies continue to lose market share. (See How the Pharmacy Industry Ch-ch-changed in 2012 .) The top five dispensing pharmacies—CVS Caremark, Walgreens, Express Scripts, Rite Aid, and Walmart—account for almost two-thirds of U.S. prescription dispensing revenues. (See 2012 Market Share of Top Pharmacies .) The largest self-warehousing chain drugstores and mail pharmacies continue to buy brand-name drugs—but not generics—via a drug wholesaler rather than directly from a manufacturer. (See CVS Caremark Renews with Cardinal and McKesson and McKesson/Rite Aid: The Early Bid Catches the Contract .) These large customers are much less profitable for wholesalers.

Risk and Reward from the Generic Wave —Over the next few years, an unprecedented volume of brand-name drugs will lose exclusivity and face generic competition. (See A New Generic Wave Update, Courtesy of Express Scripts .) The substitution of generic drugs for brand-name drugs will reduce drug wholesalers’ revenue growth. Wholesalers will benefit from this wave, since a majority of their profits comes from generic drugs. However, pressure on pharmacy profits from generic drugs is increasing. (See What Free Generic Lipitor Says about Pharmacy’s Future .) This pressure will have a derivative effect on wholesalers, because pharmacies will be more price sensitive and require bigger discounts to remain competitive. Wholesalers are responding with novel strategies. McKesson now sells private-label generic drugs as a manufacturer under the NorthStar Rx brand. AmerisourceBergen entered into a unique arrangement that allows it to purchase generic drugs via Walgreens Boots Alliance Development (WBAD), the Swiss joint venture formed in August by Walgreens and Alliance Boots. (See Making Sense of ABC-Walgreens-Alliance Boots .)

The Battle for Control of Specialty Drugs —Third-party payers are becoming dissatisfied with the buy-and-bill process for specialty pharmaceuticals covered under a patient’s medical benefit. (See The Future of Buy-and-Bill According to Payers and Oncology Practices .) In response, some payers are replacing the specialty distributor-to-provider distribution channel with a specialty pharmacy-to-provider distribution channel. (See Specialty Pharmacies Keep Gaining on Buy-and-Bill .) Specialty distributors also face risks as health systems acquire oncology practices. (See What’s Behind AmerisourceBergen’s Disappointing Oncology Results? )

2013 Distribution Trends Report

MDM’s annual distribution trends report provides a look at the key trends, opportunities and challenges facing wholesaler-distributors across distribution sectors. The report also includes a snapshot of sector-specific trends.

Lupin Pharmaceuticals, Inc #pharmaceutical #healthcare #companies

#lupin pharma


Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.

Lupin Limited, headquartered in Mumbai, India, is strongly research focused. It has a program for developing New Chemical Entities. The company has a state-of-the-art R 2010, Lupin Pharmaceuticals, Inc. All Rights Reserved.

Pharma Supply Chain #bio #pharmaceutical #companies

#pharma supply


POBOS™ Supply Chain measures end-to-end supply chain performance from supplier to wholesaler. Benchmarked dimensions include service, capital, cost, and capabilities. Ensures apple-to-apple comparison by detailed validation of metrics and definitions, and normalization of key performance metrics based on structural factors. The database covers 20 participants.

Data collection effort:

At company and country/site level

Estimated 3-4 days of time from SCM and Finance



  • What is POBOS
  • How POBOS can help
  • Contact POBOS
  • About McKinsey Co.

Pharmaceutical firm Teva to axe jobs at its Runcorn manufacturing site – Liverpool Echo #pharma

#teva pharma jobs


Pharmaceutical firm Teva to axe jobs at its Runcorn manufacturing site

The Teva pharmaceuticals site on Aston Lane South in Runcorn. Picture: ROB STAFFORD

The Runcorn operation of pharmaceutical company Teva has announced plans to make around 60 redundancies as part of a shake-up to improve its offer.

Teva said it would try and keep job losses to a minimum by identifying redeployment opportunities where possible.

The firm is an Israeli-American multinational pharmaceutical company headquartered in Petah Tikva, Israel and has four main locations in the UK which include a distribution centre in West Yorkshire, offices in Harlow, packaging operations facility in Eastbourne and manufacturing facilities in Runcorn.

It said the proposals were announced to the workforce last week as part of a long-term plan to “ensure the future sustainability of the site in an increasingly competitive global environment for the production of complex pharmaceutical products”.

Search here for jobs in Liverpool and Merseyside

It added its plans are aimed at securing the future success of the site and maintaining its commitment to manufacturing in Runcorn.

“The transformation we are undertaking requires investment in the skills and capabilities of our employees on the Runcorn site, building their technical expertise, and increasing the number of specialist roles in order to support the greater use of technology and automation now required in complex drug process development and manufacture.

“As part of this planning for the future, Teva last week announced consultation on a restructure aimed at delivering a broadening of the skills of the majority of employees, but alongside this the loss of a number of roles from the current organisation.”

The company added: “The proposed restructure would involve the potential loss of around 80 positions, and the creation of approximately 20 new specialist roles reflecting the overall upskilling of the site.

“We will give all Teva employees the fullest support through the forthcoming period of change.”

During the consultation period Teva said it will endeavour to mitigate the number of roles potentially lost and wherever possible to source suitable alternative redeployment opportunities within Teva for colleagues at risk of redundancy.

“Where this is not possible, Teva will provide outplacement assistance to help people find jobs outside Teva.”

Last month Teva announced proposals to build a ‘high technology’ training facility on the first floor of its site on Aston Lane North.

Documents lodged with the planning application to Halton Borough Council said Teva bought the site in 2006 and since then has invested 90m in the Runcorn operation and created 400 jobs, not including support staff and trades.

Marketing Pharmaindustrie Jobs #watson #pharma



Marketing Pharmaindustrie Jobs Stellenangebote

Convensis GmbH – PR-Trainee Health-Care (m/w) gesucht in Stuttgart.

Hintergrund (Biologie, Ökotrophologie, Pharma etc.) Erste Erfahrungen in einer Kommunikationsagentur (Praktikum o.ä.) Leidenschaft, für verschiedene Branchen. Wir bieten Spannende Themen, innovative und abwechslungsreiche Projekte Ein hohes Maß an Eigenverantwortung.

in.vent DIAGNOSTICA GMBH – Mitarbeiter (m/w) im Bereich Marketing und Vertrieb gesucht in Hennigsdorf.

Mitarbeiter (m/w) im Bereich Marketing und Vertrieb in.vent DIAGNOSTICA GMBH Hennigsdorf Entwicklung von Marketing -/Vertriebsstrategien, haben sie sich als betriebswirt (bereich marketing /kommunikation) mit hoher affinit t zur gesundheitsbranche zus tzlich.

Hennig Arzneimittel GmbH & Co. KG – Technology Transfer Manager Pharma (m/w) gesucht in Fl rsheim am Main.

Technology Transfer Manager Pharma (m/w) Hennig Arzneimittel GmbH & Co. KG Fl rsheim am Main Planung und Durchf hrung, unabh ngiges mittelst ndisches familienunternehmen mit ber 300 mitarbeitern unser kompetenzspektrum umfasst.

careforce marketing & sales service GmbH – Pharmaberater/-referent (m/w) Indikation Herz-Kreislauf gesucht in Berlin, Bremen, Frankfurt (Oder), G strow, K ln.

Indikation Herz-Kreislauf careforce marketing & sales service GmbH Berlin, Bremen, Frankfurt (Oder), G strow, K ln, au endienstlinien sie erwartet eine pers nliche betreuung eine langfristige perspektive sowie spannende weiterbildungsm glichkeiten.

careforce marketing & sales service GmbH – Fachberater/in Direktvertrieb gesucht in Berlin, Heidelberg, Kaiserslautern, M nchen, Trier.

Fachberater/in Direktvertrieb careforce marketing & sales service GmbH Berlin, Heidelberg, Kaiserslautern, M nchen. ber 16 jahren pharmaunternehmen mit dem einsatz von au endienstmitarbeitern sowie fach- und f hrungskr ften.

careforce marketing & sales service GmbH – Gesundheits- und Krankenpfleger/in f r den Homecare-Au endienst Indikation Neurologie gesucht in Bundesweit.

Indikation Neurologie careforce marketing & sales service GmbH Bundesweit Ihre Aufgaben umfassen Besuche in Kliniken und, von Kundenbed rfnissen;. unterst tzt seit ber 16 jahren pharmaunternehmen mit dem einsatz von au endienstmitarbeitern.

careforce marketing & sales service GmbH – Fachreferenten (m/w) Indikation Neurologie gesucht in Bundesweit.

Indikation Neurologie careforce marketing & sales service GmbH Bundesweit Fachliche Beratung und Betreuung von Allgemeinmedizinern, einsatz von au endienstmitarbeitern sowie fach- und f hrungskr ften im fokus: die erfolgreiche marktpr senz.

DENK PHARMA GmbH & Co. KG – Sales Manager (m/w) gesucht in M nchen.

Sales Manager (m/w) DENK PHARMA GmbH & Co. KG M nchen Wir bieten Ihnen Gestaltungsspielraum und schnelle Entschei dungen;, unter nehmen mit sitz in m nchen unser ziel ist es unseren patienten weltweit die gleiche hochwertige arzneimittelqualit t.

careforce marketing & sales service GmbH – Klinikreferenten (m/w) Indikation Herz-Kreislauf gesucht in Hamburg, Kiel, Gie en, Bad Homburg, Wiesbaden.

Indikation Herz-Kreislauf careforce marketing & sales service GmbH Hamburg, Kiel, Gie en, Bad Homburg, Wiesbaden Betreuung, marktpr senz der produkte renommierter pharmaunternehmen als bewerber profitieren sie von unserer langj hrigen.

Pharma FGP – Manager Quality Assurance (w/m) gesucht in Gr felfing.

Manager Quality Assurance (w/m) Pharma FGP Gr felfing Dokumentation und Nachverfolgung von GMP-relevanten Ereignissen, wir als bestes otc–unternehmen 2015 ausgezeichnet zu unserem erfolgreichen produktportfolio z hlen inzwischen mehr.

Pharmacom Labs Worldwide Official Distributor since 2008 – Buy Here #pharma #logistics



Trenbolone for the Very First Steroid Cycle

Q: Your articles have two pieces of advice that are totally contrary to recommendations I read on boards everywhere. One, even for a guy s very first cycle you seem to like choosing trenbolone. Everywhere else, the vets shoot that down when anyone suggests that s what they want to do for a first cycle. You also write cycles up around a gram per week for first cycles. Same thing. Are those old recommendations which you ve since changed, or is there a reason behind them?

A: I still often recommend those kinds of cycles as first cycles.

Why I do so is a combination of experience and some specific reasoning.

I continue to recommend cycles of these types because they work extremely well. They never disappoint. In contrast, cycles of the type often recommended on boards and the like frequently disappoint, or require extended time to provide much result.

There hasn t been an adverse side effect reason to stop recommending these cycles. With correct combination of steroids, and anti-aromatase use when using larger amounts of aromatizable steroids, side effects at the 1000 mg/week level are usually not problematic for those who are careful with what they are doing.

As for trenbolone. a very small percentage do indeed find it unsuitable for them entirely, but the great majority can use at least 37.5 mg of trenbolone acetate per day, and a large majority have no real problem with 50 mg/day. The most common issue is night sweats, but that s a harmless price to pay.

When people agree with trenbolone as a suitable choice for later cycles but not the first, this makes no sense as there s no regard in which previous experience makes a difference. If trenbolone is suitable for an individual, it will be just as suitable in a first cycle as in a later one. Anabolic steroids are not like narcotics: it s not the case that tolerance must be or is developed.

Why have such fast gains as these higher dose cycles promote, though? Is there really a need for the beginner to make really fast gains, as occurs with such cycles and proper training and nutrition?

Well, a beginner, as with anyone but even moreso, wants to gain some amount. If he can gain an amount he s thrilled with in a short time, then he ll be happy with a short cycle. If he gains little in a short period of time, then he won t be happy with that, and will seek longer cycles.

I would far rather see the beginner use short cycles, no more than 8 weeks and in some instances as little as 2 weeks, and enjoy fast recoveries rather than see him remain on steroids for 12 or 14 weeks, or even longer, trying to eke out results from marginal dosing. There are many reasons for preferring shorter cycles, including better recovery. Short cycles do not work well with marginal dosing.

Marco Pharma Oral Health – Peppermint Oil – fl #abbott #pharma

#marco pharma


Marco Pharma Oral Health Peppermint Oil 0.338 fl. oz (10 ml)

Follow practitioner s advice. These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose,š treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious medical condition.

About Supplements Vitamins
“Forget the mass merchants of cheap, low-grade health supplements and find pure, healthy goodness at With over 15,000 pharmaceutical grade health products from over 90 brands like Thorne, Metagenics, Biotics, and more, customers can shop by brand or category for the purest and highest-grade natural supplements available—all at great prices. At, products are always stored under climate-controlled conditions and properly rotated for guaranteed freshness. With hard-to-find brands, personalized customer service, and fast, economical shipping, great health is only a click away at” — Supplements Vitamins; More Details

Related Products:



PMT is a female multivitamin. It provides multiple nutrients to support healthy female endocrine function. These statements have not been evaluated by the Food and Drug Read More

  • Follow practitioner s advice. These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose,š treat or cure Read More

  • Lecithin is a natural substance found in cell membranes and is manufactured in the liver from dietary choline. It contains a mixture of phosphatides, including phosphatidyl Read More


    Women who consume healthful diets with adequate folic acid may reduce their risk of having a child with birth defects of the brain or spinal cord. Read More


    Etherium Gold promotes mental clarity and enhances focus and concentration. Etherium Gold increases the production of alpha brain waves which improves learning ability, enhances creativity and Read More

    Most Viewed

    It s important that you take care of your cardiovascular system in order to stay active and healthy. Eating a well-balanced diet that s low in fat and Read More

    Our Picks

    Improve your digestive health and fight microbial conditions with Oil of Oregano Blend from NOW Essential Oils. This oil may also reduce joint pain and respiratory Read More

  • 10 Ways to Invest in Pharmaceuticals With ETFs #pharma #code

    #pharma etf


    10 Ways to Invest in Pharmaceuticals With ETFs

    When it comes to health care, biotech is the sizzle, but pharmaceutical stocks are the steak. Big pharma stocks are financial tanks, sporting massive war chests that fund research and development, as well as acquisitions that bring in robust new drug pipelines. Pharma stocks typically don’t offer breakneck growth, but they provide a lot more stability than their growthier counterparts, and often dole out significant income to boot. If you’re looking to access a huge swath of the pharma space, you can do so via these exchange-traded funds.

    SPDR S P Pharmaceuticals ETF (ticker: XPH )

    SPDR S P Pharmaceuticals ETF (ticker: XPH )

    The SPDR S P Pharmaceuticals ETF is one of the cheapest and most balanced ways to play the pharmaceutical space. It’s simple: XPH holds 40 companies that are engaged pharmaceutical treatments, and it does so in an “equal weight” format. Every quarter, XPH rebalances so it holds every stock at the same weight. This ensures that companies like $622 million Relypsa (RLYP ) has just as much of an effect on the fund as $311 billion titan Johnson Johnson (JNJ ).

    Expenses: 0.35 percent, or $35 annually per $10,000 invested

    VanEck Vectors Pharmaceuticals ETF (PPH )

    VanEck Vectors Pharmaceuticals ETF (PPH )

    The PPH, while not equal-weighted, still is a fairly balanced fund, though it’s not as broad as the XPH. PPH invests in 26 pharmaceutical-related companies – and “related” is the key term there, as we’re not just talking about drugmakers, but also companies that help distribute pharma treatments. That allows for the inclusion of companies like McKesson Corp. (MCK ), which delivers pharmaceuticals, as well as other health care-related products. Top holdings include Pfizer (PFE ) and Bristol-Myers Squibb Co. (BMY ).

    Expenses: 0.36 percent (after a 5-basis-point fee waiver)

    PowerShares Dynamic Pharmaceuticals Portfolio (PJP )

    PowerShares Dynamic Pharmaceuticals Portfolio (PJP )

    The PJP puts stocks through a screen that looks for quality, value and momentum criteria, among others. The end result is a group of just 23 stocks, and while top holdings do include traditional names like BMY and PFE, the fund is also heavy in biotechnology stocks such as Amgen (AMGN ) and Gilead Sciences (GILD ). PJP gives investors a bit more explosive upside than they would in funds like XPH and PPH; the downside is they’re more susceptible to the violent downturns in biotech.

    Expenses: 0.56 percent

    iShares U.S. Pharmaceuticals ETF (IHE )

    iShares U.S. Pharmaceuticals ETF (IHE )

    iShares’ IHE fund is a who’s who of American pharmaceutical companies, and at 42 holdings, it’s the broadest collection of pharma stocks on this list so far. The problem is, IHE is market cap-weighted. so America’s biggest pharma firms also exert the most influence. JNJ represents more than 10 percent of the fund, and top holdings PFE, BMY, Merck Co. (MRK ) and Eli Lilly and Co. (LLY ) combine to account for more than 40 percent of the ETF’s weight.

    Expenses: 0.43 percent

    VanEck Vectors Generic Drugs ETF (GNRX )

    VanEck Vectors Generic Drugs ETF (GNRX )

    Bloomberg research shows that over the next 10 years, more than $190 billion in brand-name drug money is expected to come off the table as 150-plus products go off-patent. That money will be siphoned off into generic drugmakers’ pockets. GNRX invests in 80 pharma companies that already derive (or “could” derive) a significant portion of revenues from generics, including top holdings Baxalta (BXLT ) and Teva Pharmaceuticals Industries (TEVA ). The ETF is a new one, having started in January.

    Expenses: 0.55 percent (after a 10-basis point waiver)

    Health Care Select Sector SPDR Fund (XLV )

    Health Care Select Sector SPDR Fund (XLV )

    The XLV is perhaps the most well-known name in health care funds. State Street Global Advisers’ fund has been around since 1998 and has amassed a whopping $12.2 billion in assets under management. No wonder – even with the pullback of the past few months, XLV has doubled investors’ money over the past five years, beating the Standard Poor’s 500 index by more than 40 percentage points. Not bad for a diversified blue-chip fund.

    Expenses: 0.14 percent

    SPDR S P International Health Care Sector ETF (IRY )

    SPDR S P International Health Care Sector ETF (IRY )

    IRY offers investors a health care investment with an international bent. This ETF is similar to XLV in that it includes a number of different health care industries, but IRY is a much purer way to play the pharmaceutical space, as more than 70 percent of the fund leans toward that part of the sector. While 21 countries are represented, the bulk of the fund is invested in Switzerland, Japan and the United Kingdom – and that shows in top holdings such as Novartis (NVS ) and GlaxoSmithKline (GSK ).

    Expenses: 0.4 percent

    Direxion Daily Pharmaceutical Medical Bull and Bear 2x Shares (PILL. PILS )

    Direxion Daily Pharmaceutical Medical Bull and Bear 2x Shares (PILL. PILS )

    If you’re looking to make an exaggerated short-term bet on pharmaceuticals – either on the bull side or the bear side – you can do so with Direxion’s respective funds. PILL and PILS are designed to provide 200 percent and -200 percent, respectively, of the daily return of the Dynamic Pharmaceutical Intellidex index – the same index followed by the PJP. As is the case with any leveraged fund, note that PILL and PILS are not meant to be held for long and instead should be used for quick swing trades.

    Expenses: 0.8 percent

    See More

    Pharma biotech jobs #what #is #big #pharma

    #pharma biotech jobs


    278BioTech / Pharmaceuticalindustry jobs

    • West
    • Login to view salary
    • Responsibilities: Provide support for finance activities: closing, balance sheet. Responsible to maintain and reconcile general ledger. Review and perform monthly amortization of prepayment on monthly basis prior to month-end close. Assist in preparation of statutory and taxation schedules and.

    Associate Engineer (MNC / Pharmaceutical / East / 5D / Up $3.5k / GMP / Gxp Doc / )

    • East (Singapore)
    • Login to view salary
    • Our Clients A fast growing and leading pharmaceutical company of high establishment is undergoing expansion plans in the region to support the.
    • West
    • Login to view salary
    • Responsibilities: Carry out analytical testing on Finished Products and Raw Materials to support production activities, and the needs of other departments/sections such as A TG, Material Management, Procurement, and E M and to ensure timely release of FP and RM. Investigates and documents.

    Engineer, Automation

    • Global healthcare leader that offers career growth opportunities
    • Positive and collaborative work environment
    • A shared purpose in saving and improving lives around the world
    • West
    • Login to view salary
    • Under the supervision of the IPT Automation Lead, Automation Engineer is responsible for providing technical support in the field of automation.

    Medical Officer

    • West
    • Login to view salary
    • Job Summary Perform Medical Monitoring (Assess feasibility, give scientific input from start up through to close out, review protocols). Maintain.

    Medical Sales Executive

    • East
    • Login to view salary
    • Responsibilities Promoting and selling Traditional Chinese Medicine (TCM) products to Chinese medicine clinics and medical halls. Contact new or.

    Sr Software Engineer (Bioinformatics) – (5846BR)

    • Singapore – Singapore
    • Do you want to make a difference? Illumina’s mission is to improve human health by unlocking the power of the genome. If that inspires you, let’s.

    Organizational Learning Executive

    • West
    • Login to view salary
    • Responsibilities: Address training needs (functional skills and development training) Conduct Annual Training Needs Analysis with business partner to determine departmental training requirements to meet business needs. Monitor departmental training status with individual leaders on regular basis.
    • West
    • Login to view salary
    • Responsibilities: Perform studies to identify and improve existing process efficiency. Conduct process validation in coordination with Technical Services, QA, E M and other departments. Monitor and report indicator of process performance. To lead in motivating and reinforcing expected.

    Facility Security Maintenance Specialist – MNC (Medical) / North / S$2.5K to $3.1K

    • North
    • Login to view salary
    • US MNC (Medical) / North/Up to S$3.1K
      Familiar with preventive and corrective maintenance for all Security systems -CCTV, Card Access System, Door Alarm System, and etc
      12 month renewable contract
      Experience in Manufacturing Industry preferred
      Our client.

    Senior / Automation Engineer – Life Science MNC

    • East
    • Login to view salary
    • Strong hands-on experience in equipment, Jigs Fixture Factory automation and medical equipment design experience preferred.
      Opportunity to be stationed in US Plant (6- 18 months) for product transfer training
      Singaporean only
      Our client, a US Life Science.

    Quality Engineer-Software Validation (US Biomedical Manufacturing)

    • East
    • Login to view salary
    • Responsibilities: Responsible to assure that manufacturing processes comply with the product specification and regulatory government agencies requirements. Provide mechanisms for controlling the total quality and establish ways of evaluating the quality of our products. Responsible to develop.

    URL Pharma – latest news, breaking stories and comment – The Independent #italian #pharmaceutical #companies

    #url pharma


    URL Pharma

    We’ve noticed that you are using an ad blocker.

    Advertising helps fund our journalism and keep it truly independent. It helps to build our international editorial team, from war correspondents to investigative reporters, commentators to critics.

    Click here to view instructions on how to disable your ad blocker, and help us to keep providing you with free-thinking journalism – for free.

    Thank you for your support.

    How to disable your ad blocker for

    Adblock / Adblock Plus

    • Click the Adblock/Adblock Plus icon, which is to the right of your address bar.
    • On Adblock click “Don’t run on pages on this domain”.
    • On Adblock Plus click “Enabled on this site” to disable ad blocking for the current website you are on. If you are in Firefox click “disable on “.

    Firefox Tracking Protection

    • If you are Private Browsing in Firefox, “Tracking Protection” may cause the adblock notice to show. It can be temporarily disabled by clicking the “shield” icon in the address bar.


    • Click the Ghostery icon.
    • In versions before 6.0 click “whitelist site”.
    • In version 6.0 click “trust site” or add to your Trusted Site list.
    • In versions before 6.0 you will see the message “Site is whitelisted”.
    • Click “reload the page to see your changes”.


    • Click the uBlock icon.
    • Then click the big power button to whitelist the current web site, and its state will be remembered next time you visit the web site.
    • Then reload the page.

    Sales Representative, Pharmaceuticals Salary #biggest #pharmaceutical #companies

    #pharmaceutical rep


    Sales Representative, Pharmaceuticals Salary

    Job Description for Sales Representative, Pharmaceuticals

    Sales representatives in the pharmaceutical industry have a number of responsibilities, including calling on existing and potential clients to establish new accounts, obtain orders, service existing accounts, and implement brand strategies intended to convey the company’s marketing message. They must also adjust the content of sales presentations to be client-specific and reflect any changes in products, services, policies, or competitive development.

    Pharmaceutical sales representatives strive to resolve customers’ complaints and concerns by investigating any issues that arise, developing solutions, and submitting applicable reports or recommendations to management. They also maintain sales records and histories and report sales activity to management via daily, weekly, or monthly reports and analyses. They typically meet with a variety of professionals, including medical personnel such as physicians, pharmacists, nurses, and technicians, medical office management, staff of medical facilities, and existing or potential clients, and often meet with clients at their own locations.

    This work can be both physically and mentally demanding, and long hours walking, standing, and traveling between multiple locations may be necessary. Pharmaceutical sales representatives work primarily during daytime hours, but may also attend meetings and work-related functions in the evening and on weekends. Mental demands of the position include staying up-to-date with industry changes, products, scientific updates, and medical issues, communicating information about products to a variety of clients, addressing clients’ questions and concerns, staying organized, and effectively reporting to management, and they typically report to a sales or marketing manager within the company.

    Pharmaceutical sales representatives must be neat and professional in appearance and demeanor and have proven sales experience, excellent communication skills, strong time-management and organizational skills, some familiarity with medical-related science and medical issues, and proficiency with computers, tablets, mobile devices, databases, and the internet. These representatives may work on teams or individually and should participate in ongoing education, review trade literature and publications, participate in professional societies, and establish personal networks to stay up-to-date with the latest industry trends and scientific updates.

    A bachelor’s degree in marketing or a related field, knowledge of basic medical terminology, and an understanding of the regulations related to the pharmaceutical industry are generally required for this position, and prior sales experience may also be required by some employers.

    Sales Representative, Pharmaceuticals Tasks

    • Attend special training of products or services to understand technical aspects of solutions.
    • Sell the organization’s technical products to established customers or develop new prospects within assigned territory.
    • Build relationships and identify the prospect’s need for the products or services.
    • Prepare and maintain records for sales leads and progress status of accounts.
    • Emphasize product features based on analyses of customers’ needs, and on technical knowledge of product capabilities.

    Common Career Paths for Sales Representative, Pharmaceuticals

    119 Pharmaceutical Sales Representative Jobs in Dallas, Texas #pharmaceutical #manufacturing #jobs

    #pharmaceutical companies in dallas tx


    Job Search Tips

    The ZipRecruiter job matching algorithm analyzes millions of jobs from hundreds of job boards to instantly return the most relevant results. Here are some additional tips to help you optimize your search:

    Job titles are best:

    Searching for a specific job title provides more accurate results than company names or other keywords. software engineer is better than coder. and registered nurse is better than hospital .

    Zip code can help narrow your location:

    For location, a zip code is generally more precise than entering city, state.

    You can use quotes:

    Surround multiple terms in quotes to treat them as a phrase, like: program manager or dental hygenist .

    You can exclude certain terms:

    Enter a minus sign before any terms you want to exclude, like: -travel or – entry level .

    You can require certain terms:

    Enter a plus sign before any terms you want to require, like: +full-time or + full benefits .

    119 Pharmaceutical Sales Representative Jobs in Dallas, Texas

    Marco Pharma #spectrum #pharma

    #marco pharma


    Welcome to Marco Pharma’s Retail Store

    Marco Pharma carries a selection of products carefully chosen by physicians well experienced in biological therapies. Not only do we import standardized and pharmaceutical-grade medicines from as far away as Germany and the Pacific Islands, but we also bottle and label our medicines locally in Oregon.

    Acusine Homeopathic Nasal Spray

    Contessa Homeopathic Liquid (Single or Pack of 2 bottles)

    MarcoSport Blue Cooling Gel

    MarcoSport Green Massage Cream

    MarcoSport Red Warming Cream

    Wow Drops (Pack of 2 bottles)

    Quick Links

    Get In Touch

    Marco Pharma International LLC
    851 NW Highland Street
    Roseburg, OR 97470
    Sales: 800-999-3001

    To be niche players in neurology oncology: Eisai Pharma #pharma #marketing #research

    #eisai pharma


    While most Japanese drugmakers have been cautious post the Daiichi Sankyo’s crisis in Ranbaxy, Eisai Pharma is the only Japanese pharma company that continues to place its bet on the Indian pharma space. The company has consolidated its manufacturing and commercial operations in India and is adopting a multipronged growth strategy.

    The company which has been operating a Greenfield manufacturing facility in Vizag and is looking to grow its business in India. The plant currently caters entirely to the Japanese market. However Eisai wants to convert its India facility into a global sourcing hub that will export products to other international markets as well.

    Sanjit Lamba, MD & CEO of the company said: We are looking at Vizag as a global supply hub, so we will do not differentiate when we produce for India or other markets. We will be expanding sourcing for other markets.

    Currently, the Japanese drug maker has a limited presence in India; it sells 20 drugs, most of which are imported. The company also has marketing alliances with GSK for a gastric disorder drug and with Wockhardt for a neuropathy drug but now eisai wants to scale up in India.

    It is company’s plan is to build focus business units in neurology, oncology and multi-specialty therapy areas. They also plan to launch 2 new drugs every year, double the field force to 250 personnel over the next 3 years and, explore strategic brand acquisitions and marketing alliances

    Eisai is a late entrant in the highly competitive Indian pharma market. Although it acknowledges the challenges around pricing, IP protection and cost structures, the company believes its focused manufacturing strategy will help it catch up with competition fairly quickly.

    Below is the interview transcript of Sanjit Singh Lamba s interview with CNBC-TV18 s Archana Shukla.

    Q: What would you focus on now?

    A: We want to remain focusedon two therapy areas, neurology and oncology. We are building our portfolios in such a way so that we become a niche organisation into these two therapy areas.

    With neurology we already have presence with Aricept and also products like Zonegran. So, we are looking at one product in neurology and one product in oncology immediately.

    We have a very healthy research pipeline including oncology and neurology products. So, we would be looking at launching these products in India over a period of time.

    Q: Mostly exporting from Vizag facility, what is the plan going forward? Are you looking for production more for domestic purposes now?

    A: We would look at the manufacturing facility in Vizag as a global supply hub which can meet the requirements of patients worldwide. We do not differentiate whether we are manufacturing for Japan or US or areas in South East Asian market or India. We have already started manufacturing for Indian market. We have a product Aricept which is being manufactured in Vizag. We have other product which is Urief which under urology segment which is right now manufactured at Vizag.

    We are looking at expanding this to other products in future where we can leverage our strengths of Vizag for India business. Other plan is we are looking at expanding our capacity both in API as well as the finished dose.

    Catalent Biomanufacturing Center of Excellence, Madison, Wisconsin – Pharmaceutical Technology #pharma #bio

    #catalent pharma


    Catalent Biomanufacturing Center of Excellence, Madison, Wisconsin, United States of America

    • Project Type Expansion
    • Location Madison, Wisconsin, US
    • Construction Started December 2011
    • Construction Completion 2012
    • Opened April 2013
    • Area 100,000ft2
    • Owner Catalent Pharma Solutions

    Catalent Pharma Solutions opened a state-of-the-art bio-manufacturing centre of excellence in Madison, Wisconsin, US, in April 2013. Following the inauguration, Catalent relocated its operations and 89 employees from a 43,000ft² facility in Middleton to the new 100,000ft² centre.

    The new facility quadruples Catalent’s manufacturing capabilities and helps to generate innovative biologic products.

    Catalent invested $29m in leasing and equipping the new site. It received $1m in job creation and job training tax credits from the state.

    Catalent’s Middleton facility details

    Catalent relocated its operations to a 100,000ft 2 facility in Middleton, Wisconsin, US.

    Catalent’s Middleton facility was equipped with biopharmaceutical development and mammalian cell line engineering capabilities. It was also capable of carrying out protein production for clinical Phase I-II trials.

    The facility used the patented gene expression (GPEx) technology used for producing stable mammalian cell lines. The technology enables current Good Manufacturing Practice (cGMP) production of biopharmaceuticals.

    The Middleton facility also included development laboratories and space for research and development and quality control. It included cGMP manufacturing suites featuring stirred tank bioreactors.

    The facility was ideal during the initial growth stages of the company in the early 2000s. It is, however, ageing and its size restricted Catalent’s bioprocess capabilities. Relocation was considered as the best solution to address these issues.

    Need for expansion of Catalent’s facilities

    Relocation to Madison was part of several strategic initiatives being undertaken by Catalent to improve its product offerings. Increase in demand for cell-line engineering was one of the main reasons for the decision to relocate.

    The new facility features significant upgrades to Catalent’s current process and manufacturing capabilities.

    In 2010, contracts requiring use of the GPEx technology had doubled and were growing by nearly 20% every year. Competition was also increasing in contract manufacturing of biologics. Companies such as ShangPharma, Lonza and DSM were expanding their offerings in the field.

    The increase in demand for Catalent’s products and manufacturing capabilities, as well as competition from other companies, resulted in a need for more space and a robust infrastructure. In December 2011, the company announced its plans to expand its manufacturing capabilities. The additional capacity provided by the new facility would help Catalent’s customers bring their products to the market faster.

    Catalent also partnered with Toyobo Biologics to increase its product offering in biologics.

    The new Madison facility

    The Madison facility was originally built in 2000 for the production of bone-scanning medical devices. It was later operated by GE Healthcare. Catalent retrofitted the facility to its standards.

    Designed for cGMP production from 10l up to 1,000l and non-GMP production up to 250l, the new facility features extensive use of single-use technologies and unidirectional flow to minimise the risk of cross-contamination. The facility is equipped with three separate cGMP-compliant production suites.

    Related Project

    Lonza Biologics completed the large-scale expansion of their facility in Portsmouth, New Hampshire, Pease International Tradeport, US in 2004.

    The Middleton facility employed 200l stainless-steel bioreactors. The new facility shifts the use of single-use bioreactors with capacities ranging from 50l to 100l. This increases Catalent’s production capacity for Phase I and II clinical trials.

    Single-use bioreactors help to increase the number of batches produced. They provide Catalent with greater flexibility in terms of cleaning and changeover. This flexibility is essential in an environment where Catalent has to work on different proteins supplied by several customers.

    The increased capacity from stainless-steel bioreactors helps Catalent to scale up its manufacturing capabilities according to customer requirements.

    Catalent installed one single-use bioreactor at the Middleton facility. This enabled employees to familiarise themselves with the system.

    Production at the Wisconsin facility

    The new facility increases the efficiency and output of the GPEx technology. It uses retrovector technology, which enables accurate transduction of targeted cells. Any kind of complementary DNA can be targeted using the technology to generate a mammalian cell line of customer’s choice.

    The technology enables generation of stable mammalian cell lines in 4.5 months compared with 18 months using conventional technologies. It is more efficient and reduces costs by halving the development time.

    Related Content

    Senator calls for investigation of Purdue Pharma following Times story on OxyContin – LA Times

    #purdue pharmaceuticals


    Senator calls for investigation of Purdue Pharma following Times story on OxyContin

    A U.S. senator on Friday called for federal investigations of OxyContin s manufacturer in response to a Los Angeles Times report that found the bestselling painkiller wears off early in many patients, exposing them to increased risk of addiction.

    Sen. Edward J. Markey, a Massachusetts Democrat whose state has been hit hard by prescription drug abuse, urged the Justice Department. the Food and Drug Administration and the Federal Trade Commission to launch probes of drugmaker Purdue Pharma.

    OxyContin s main selling point is that it lasts 12 hours. The Times investigation published this month found that when the effects don t last, patients can suffer symptoms of narcotic withdrawal, including intense craving for the drug, and experience a cycle of agony and relief that experts say promotes addiction.

    OxyContin is the original sin of the current opioid epidemic. Sen. Edward J. Markey

    The newspaper found that Purdue had evidence of the problem for more than two decades, but continued to insist the drug lasted 12 hours, in part, to protect its revenue. OxyContin s market dominance and premium price hinge on its 12-hour duration. Purdue instructed doctors who complained about the drug s duration to prescribe stronger, but not more frequent, doses. Research shows that patients taking high doses of opioids are at greater risk of an overdose and death.

    ‘You want a description of hell?’ OxyContin’s 12-hour problem

    Harriet Ryan, Lisa Girion and Scott Glover

    Harriet Ryan, Lisa Girion and Scott Glover

    These are serious allegations, Markey wrote of The Times findings in a letter to Atty. Gen. Loretta Lynch. They raise questions about ongoing deception by Purdue, harm to the public, continued costs to the United States, and the availability of further judicial recourse against Purdue

    In a separate letter to the heads of the FDA and FTC, Markey called OxyContin a leading culprit in the current opioid and heroin overdose epidemic. More than 194,000 people have died from overdoses involving opioid painkillers since 1999 and abuse of those drugs is blamed for the resurgence in heroin addiction in the U.S. Markey said the agencies should proactively warn prescribers, patients, and the general public about problems the newspaper identified with OxyContin.

    Purdue, a family-owned Connecticut company that has collected more than $31 billion from OxyContin sales, rejected The Times findings. In a statement, the company said Purdue shared Markey s concerns about the opioid epidemic, but noted that the FDA approved OxyContin as a 12-hour drug.

    We promote our medicines only within the parameters approved by FDA and, given FDA has not approved OxyContin for eight-hour use, we do not recommend that dosing to prescribers, the statement said.

    A Justice Department spokesman said the department was reviewing the letter and an FTC spokesman confirmed the agency had received the letter, but declined comment.

    An FDA spokeswoman said the agency was reviewing the letter and would respond directly to Markey. Previously, the agency spokeswoman told The Times the FDA will revise labeling as necessary to improve proper prescribing and treatment, but also placed responsibility with doctors.

    It should be well understood by physicians that there will be some individual variability in the length of time that patients respond to this drug, the spokeswoman said.

    Dr. Lewis Nelson, a New York University professor of emergency medicine who has advised the FDA on risks of prescription opioids, said that in his experience teaching physicians around the nation, many doctors have forgotten their medical school training about how opioids work in individuals.

    I don t think the average doctor would recall the difference between changing a dose to q8, medical shorthand for every 8 hours, or increasing the dose, Nelson said.

    He said the Times findings were credible and the FDA should change the label.

    It would seem like this is a very fixable problem, Nelson said.

    OxyContin s history is inextricably linked with the prescription drug epidemic. Purdue launched the drug in 1996 with an aggressive marketing campaign to primary care doctors that presented the painkiller as appropriate treatment for back aches and knee pain. Purdue and three company executives pleaded guilty in 2007 to federal charges of drug misbranding for what the company acknowledged was an attempt to downplay OxyContin s risk of addiction. They were ordered to pay $635 million.

    Markey has been an outspoken critic of the role of pharmaceutical companies and the FDA in the opioid crisis. In January, he temporarily blocked the nomination of Dr. Robert Califf as FDA commissioner to protest the agency s approval process for opioids, including its August decision to approve OxyContin for use in children as young as 11. Califf was later confirmed.

    OxyContin is the original sin of the current opioid epidemic, Markey said in a statement to The Times. For years, Purdue Pharma lied to federal regulators and the public about the addictiveness of OxyContin and countless patients got hooked on this deadly painkiller. We need to know if Purdue once again lied about the longevity of OxyContin s pain-relieving properties and hold Purdue accountable.

    Markey s focus on opioids reflects Massachusetts severe problem with painkillers and heroin, which has been embraced by many prescription drug addicts as a cheaper alternative to pills. The death rate from opioid overdoses is more than twice the national average and climbing. More than 1,300 people died from opioid-related causes last year, according to the Massachusetts Department of Public Health.

    Four people die every day and we haven t been able to bend the trend, said Marylou Sudders, the commonwealth s secretary of health and human services. That s not a problem. That is a crisis.

    Sudders attributed the problem, in part, to doctors over-prescribing opioids. A state law passed in March requires doctors to receive additional training and limits first-time opioid prescriptions to seven days.

    The Times report concerned an issue that went largely unnoticed in the scrutiny of OxyContin: the drug s duration. Purdue s clinical trials demonstrated the problem. In the first test on patients, for example, OxyContin wore off early in about half of participants.

    After the drug hit the market, the company was confronted with additional evidence, including complaints from doctors and research by outside scientists.

    In his letter to Lynch, Markey wrote that if warranted the Justice Department should try to recoup taxpayer dollars that federal healthcare programs may have needlessly and unnecessarily spent on OxyContin prescriptions.

    12:52 p.m.: This post has been updated to include statements from the FTC and statistics about opioid deaths in the U.S.

    10:33 a.m.: This post has been updated to include statements from Purdue.

    9:46 a.m.: This post was updated to include responses from the Justice Department and the FDA.

    This article was originally published at 7:10 a.m.

    Drug Injury Attorney in Dallas, Texas #d #pharma

    #pharmaceutical companies in dallas tx


    24/7 AVAILABILITY (214) 219-4878

    Dallas Drug Injury Lawyer

    Drug Injuries and Pharmaceutical Liability

    Medicine has come a long way from the early 20th century and the experiments of Alexander Fleming and Paul Ehrlich. The development of antibiotics such as penicillin ushered in a new wave of medicine which provided vaccines to children to combat most of the deadly childhood illnesses such as measles and polio. Since this point, medicine and antibiotics have grown to large proportions and are now used on a daily basis. We place our trust in pharmaceutical companies and when a drug causes severe injuries, the responsible party deserves to be held accountable and a strong Dallas drug injury lawyer can help you get the compensation you deserve.

    Pharmaceutical Companies

    The pharmaceutical industry has shifted from an industry which helps people to one which desires a profit. Profit only comes with new medicinal revenue. As a result, pharmaceutical companies often attempt to increase profits by hurriedly rushing a new drug to market without taking the proper precautions. They additionally attempt to incentivize doctors and health care professionals who will boast the drug to their patients before any medical tests have proven any harmful effects of the drug.

    However, this lack of testing can lead to irreparable damage which pharmaceutical companies and participating health care professionals should be responsible for.

    Drug Injuries

    Drug injuries have become so widespread recently and touted throughout commercials and billboards that it makes it difficult to trust any pharmaceutical company. Several of the main drugs known to cause injuries include:

    • Xarelto: Prescription blood thinner manufactured by Bayer and marketed by Johnson Johnson.
    • Yaz: birth control medication which has been linked to blood clots and increased potassium levels in the blood.
    • Chantix. smoking cessation drug which is linked to birth defects.
    • Actos and Byetta: Diabetes drugs which have been linked to severe organ damage.
    • Eliquis. Prescription blood thinner manufactured by Bristol-Myers Squibb and Pfizer.
    • Topamax: migraine drug which has been linked to birth defects.

    There are many other types of drugs that lead to serious injuries, many even fatal. If you have been injured from a drug produced by pharmaceutical companies, do not hesitate to contact our Dallas personal injury attorney Jeff Benton today.

    The Benton Law Firm | Dallas Pharmaceutical Liability Attorney

    The Benton Law Firm handles many drug injury cases throughout the Dallas area, including the drugs listed above and many more. We understand the amount of trust you place in pharmaceutical companies and the feeling once a drug is found to injure you instead of help you. Modern medicine has evolved to prevent serious injuries from occurring and when these drugs instead cause the injuries, it leads many of us fearful to take any helpful antibiotics. If you or a loved one have been injured by a drug, you should not be forced to pay for any medical expenses associated with your injuries. Contact our law offices today to set up your initial consultation with our attorney, and our attorney will begin putting together a strategy to pursue a case against the drug manufacturer. Antibiotics and other medicine sometimes cause more harm than good, but if you and other injured clients continue to bring claims against the pharmaceutical companies, you will effectively prevent other patients from ingesting dangerous drugs.

    Practice Areas

    Request a free consultation

    Helvoet Pharma Belgium – Alken, Limburg, Belgium – Phone Number #pharma #mba

    #helvoet pharma


    Helvoet Pharma Belgium

    Map Details

    It looks like we don’t have a specific address for Helvoet Pharma Belgium, which makes giving directions tricky. This business might not have an official storefront, or it might move to multiple locations throughout the day.

    Do you have more specific information about the location of Helvoet Pharma Belgium? Why didn’t you say so? You can improve Yelp by sharing it here.

    Industrieterrein Kolmen 1519
    3570 Alken

  • Phone number +32 11 59 08 11
  • Is this your business?

    Respond to reviews and privately message customers.
    Claiming is free, and only takes a minute.

    Hey there trendsetter! You could be the first review for Helvoet Pharma Belgium.

    Is this your business?

    Claim your business page and access your free Yelp for Business Owners account.

    • Immediately update business information
    • Respond to reviews and privately message customers
    • See the customer leads your business page generates
    • Monitor how many people view your business page

    Claim This Business

    Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt #app #pharma

    #hitech pharma


    Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt Organizations (RICO) and Protein Spiking Allegations

    ATLANTA. May 12, 2016 /PRNewswire/ — Protein supplement maker Hi-Tech Pharmaceuticals, Inc. says rival MusclePharm Corp. artificially inflates the level of protein in its Arnold Schwarzenegger Series Iron Mass product and then lies to consumers about it, violating federal competition and state consumer protection laws, according to a complaint filed in Georgia federal court. The lawsuit further alleges violations of the Racketeer Influenced and Corrupt Organizations (RICO) act and protein spiking allegations involving MusclePharm Sports Nutrition’s protein supplement.

    This lawsuit comes days after Arnold Schwarzenegger terminated his relationship with MusclePharm due to years of his good name being dragged through the mud. The lawsuit alleges that MusclePharm and its former owner Brad Pyatt were engaged in a scheme to defraud consumers as to the Iron Mass product’s content, quality, characteristics, and/or ingredients, and caused and enabled consumers to purchase MusclePharm’s Iron Mass product instead of Hi-Tech’s NitroPro product.

    The lawsuit’s allegations include that MusclePharm’s label makes misleading claims about its protein content. For example, the labeling claims that the product contains 40 grams of protein per serving; however, this figure allegedly also includes the amino acid, Glycine and; the non-amino acid compound, Creatine Monohydrate. According to the lawsuit, testing reveals that the actual content per serving of protein is 19.53 grams (48.5% of label claim) once protein-spiking agents are eliminated.

    The lawsuit also alleges, “In furtherance of this scheme, MusclePharm used the Internet to disseminate its false product claims to consumers across the United States. and to enable consumers to purchase MusclePharm’s Iron Mass product online. It also used the U.S. Mail and/or other interstate carriers to ship Iron Mass to consumers throughout the United States in violation of 18 U.S.C. Section 1341. ” The suit further alleges, “Defendants have conspired to conduct and participate in the conduct of the affairs of the enterprise through a pattern of racketeering activity. That conduct constitutes conspiracy to violate Racketeer Influenced and Corrupt Organizations (RICO) 18 U.S.C. Section 1962(c), in violation of 18 U.S.C. Section 1962(d).” Passed the year after The Godfather was published, RICO is part of a 1970 law designed to allows plaintiffs to bring civil lawsuits against organizations whose members allegedly committed crimes.

    Hi-Tech Pharmaceuticals lawsuit alleges that MusclePharm and Pyatt’s Iron Mass Protein does not contain the quantity of protein as claimed on the product’s label, and also alleges the use of non-protein ingredients in protein supplement products due to a process known as “protein-spiking.” These ingredients are added to increase a protein product’s nitrogen content while allowing the manufacturer to save on protein manufacturing costs. A popularly used protein content test uses nitrogen as a measure of protein; therefore, protein spiking serves to fool consumers into believing they are receiving more whey protein than is actually contained in the product.

    About Hi-Tech Pharmaceuticals

    Hi-Tech Pharmaceuticals ( ) is a leading Sports Nutrition manufacturer. Since 1979, Hi-Tech Pharmaceuticals, Inc. and its sister company, Hi-Tech Nutraceuticals, LLC. have been providing quality custom manufacturing services to the pharmaceutical, dietary supplement and beverage industries. Hi-Tech Pharmaceuticals is a cGMP certified company that operates out of Four (4) US Production facilities and (2) Warehouses, totally over 500,000 sq. ft. The two Georgia based production facilities are both located outside Atlanta in the Norcross and Suwanee Advanced Technology areas. Hi-Tech also has Two (2) facilities located outside State College, Pennsylvania. Hi-Tech holds a Drug Manufacturing License issued by the State of Pennsylvania Food and Drug Branch and is registered as a Food and Drug Establishment with the FDA in Pennsylvania .

    Hi-Tech Pharmaceuticals is an enormously successful company that creates, manufactures and sells high-quality products sold by the large, major retailers across the United States. These retailers include: GNC, Vitamin Shoppe, Rite Aid, Kroger, Winn-Dixie, Albertson’s, CVS, Duane Reade. Hannaford, Cardinal Health, McKesson, Mclain, Harmon Stores. Fred Meyer. Osco Drugs, Supervalu, Roundy’s, Walgreens, Sav-On Drugs, Meijer, Fruth Pharmacy, Kinney Drug, Kinray, USA Drugs, A P, Kmart,,,, and over 5,000 independent drug stores, as well as in more than 80,000 convenience stores throughout the United States .

    SOURCE Hi-Tech Pharmaceuticals, Inc.

    Related Links

    Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt Organizations (RICO) and Protein Spiking Allegations

    Can I start my own pharmaceutical marketing company? If so, what can I expect from

    #pharmaceutical marketing companies


    Yes you can, it s entirely possible, in fact a good friend of mine just did it a few months ago. However, he d been in the field for almost ten years, and his partners had been in it even longer.

    The problem is getting clients. Once you have one client you re good, but that first one is really tough to land.

    Pharma companies are huge and even their smallest products are enormously expensive to develop, so while they spend a lot on marketing and advertising there s a lot riding on the success of those efforts. So getting your foot in the door is going to be tough.

    Traditionally the way it s worked is that you go work for a pharma ad agency (or in the marketing department of a pharma company – but you make a lot fewer contacts this way) for a while until you have the experience and contacts to go out on your own and start your own shop. That can take a long time – over a decade, most likely.

    Alternatively you can try to own one small component of marketing (say CRM development, some component of website design, etc.) and get some experience with non-pharma clients and then try to work your way into the world of pharma.

    This second approach is tough for two reasons. First is that you won t have any understanding of the regulatory environment that pharma marketing lives in. All branded communications for pharma products are regulated by OPDP, a division of the FDA that ensures promotional material complies with their regulatory structure. OPDP has been known to issue fines in the billions to companies that have egregiously flaunted their rules, so companies want to make sure they re compliant. All pharma companies have internal regulatory/medical/legal teams for this, but they will want to know that you have at least a baseline level of experience so that they re not redoing all of your work, and the guidelines are often not intuitive – there s no substitute for experience.

    The second problem is that you likely won t have any contacts in the industry. Because of the nature of pharma marketing there isn t a lot of crossover between pharma and other sectors, so getting experience in consumer packaged goods or B2B marketing likely won t yield you any useful contacts in pharma, and new business leads are very much driven by personal relationships in this field.

    Sorry if this comes off as overly pessimistic, but the pharma marketing agency world is not particularly startup-friendly. Without some fairly significant prior experience, or at least partnering up with someone or some people who have the required experience, it s going to be almost impossible for you to get off the ground.

    Written 89w ago View Upvotes Not for Reproduction Answer requested by 1 person

    Do you want to? Probably Not.

    Do you have a background in Pharma? If not, then run away and thank me later 🙂

    I have worked Pharma clients before and imagine the deepest darkest breaches of hell, and then multiply it by 100, and then add a few monthly letters from the FDA, add a hundred lawyers, maybe some sulfuric acid to pour into your eyes because it dulls the pain of listening to the lawyers tell you why you can t do with your marketing.

    Then imagine completing your project finally and sitting down with a nice cold one and you turn on the TV to relax and instead you see a new bill that passed saying you can t do what you just spent 8 months working on.

    Alright, now let me tell you what you should get into instead.

    It is just like Pharma, only without as many lawyers (you still have a few), and the FDA.

    Its called Nutraceuticals and its much easier to get into as a startup, plus there is a lot less regulation. You still deal with some regulation, but its a lot less.

    Basically Nutraceuticals are natural supplement products. Depending on the exact area that you go into within it, you can have some or no FDA regulation. I can t really talk about my clients much, but I can say that two of them have absolutely no FDA regulation (for now). This makes everything much easier and more fun, but its still very similar.

    Also, Nutraceuticals have great markups (aka big marketing budgets), and they are one of the hottest growing verticals right now. Check it out!

    Written 89w ago View Upvotes Not for Reproduction Answer requested by 1 person

    Future of Pharmaceutical Industry – pharma innovation gaps, patent expiry, empty drug pipelines #fosun #pharma

    #future of pharmaceutical industry


    The pharmaceutical industry is facing huge challenges – described in video above and in powerpoint slides below. Notes on content: Over the last five years there has been serious lack of innovation in pharma companies and product pipelines have been emptying. It takes up to 15 years and $1 billion in investment to bring a single new treatment to market, after which there may be as little as a decade left before patents expire. But before that happens there may be serious threats to the pharmaceutical industry from generic manufacturers. And at any point in development or after launch, an adverse problem can result in product recall. For these reasons Pharmaceutical companies tended to focus on the search for blockbuster drugs in the early years of the 2000s: drugs with expected revenues of more than $1bn a year.

    Need a world-class pharma keynote speaker? Phone Patrick Dixon now or email.

    The top 10 pharmaceutical companies have enjoyed research and development budgets greatert than the combined GDP of the world’s poorest 130 nations, yet have produced only 30% of new drugs being approved each year. The rest have largely been developed by some of the 4,000 small biotechnology companies, working on large molecule therapeutics.

    It is an immensely complicated and risky process, working through laboratory studies, animal studies and then clinical trials. A key issue for the future will be routine gene profile typing and pharmacogenomics – or matching drug therapy to someone’s genetic code. This will result in better targetting of the most effective therapies in each situation, but also in lower sales for each therapy since only those people in whom it is most likely to work will actually receive it.

    Watch out for a shift from health care or treating sickness, to wellness, disease prevention, enhanced performance and lifestyle drugs. This is the age of Viagra-like drugs, designed to rejuvenate, or to increase deteriorating function such as memory. But drugs developed for a condition like Alzheimers will also be widely used or abused, if they are shown to really stimulate human memory capacity for example.

    Expect a new emphasis also on common cellular mechanisms of disease. There are only a few ways in which human cells age for example. If we can block one or two of these mechanisms the result may be an effective treatment for a wide range of conditions which are more common as people get old – and remember that diseases of ageing drive most health care spending in developing nations. Indeed 75% of health spending in America and Western Europe is on those over the age of 65.

    Watch out for major shifts in government purchasing policies, changes in US medicare and in health insurance cover. Over the counter and pharmacists sales will grow rapidly, helped by deregulation in developed nations, allowing more products to be available without prescription, “over the counter”. Expect huge growth in so-called nutraceuticals (foods with active health-stimiulating ingredients) and cosmetics with all kinds of anti-ageing properties.

    While most budget will be spent solving common chronic diseases, expect innovation in childhood diseases, with a special focus on emerging nations, funded by philanthropic foundations. Expect major progress with new vaccines. Rheumatoid arthritis and asthma share a root cause in abnormal immune systems – expect huge research into tackling auto-immune problems.

    Expect also big investment into next generation antibiotics to solve multiple drug resistance problems, which are one of the major challenges for the future.

    Other issues include future health funding and ageing populations – contrast with emerging markets. Health economics: treatment access and justice.

    Winning the Public Debate about Pharma

    Problem: Negative public image of big pharma / pharmaceutical industry major players

    Impact: Hostile regulators, hostile media, hostile web communities, aggressive activists and analysts, loss of best talent to other industries / biotech, difficult pricing negotiations with governments etc. Cost to whole industry could be billions of dollars a year.

    Cause: Confused messages directed at analysts and consumers. Same kind of problem seen in insurance and energy industries. A simplification: Analysts: bottom line, return on equity, competitive advantage, keeping product prices high, exploiting market gaps – and by implication making as much money as possible out of as many sick people as possible. Consumers: saving lives, helping humankind, helping get safe, low cost treatments to all who need them – and by implication less concerned about things like intellectual property rights or threat from generic manufacturers. Consumers often find messages aimed at analysts offensive and bordering on unethical. Analysts often find messages aimed at consumers worrying and maybe unbusinesslike.

    Solution: simple, powerful message revealing the truth about Wyeth: an inspiring, world-changing and business success story. Use BP Chairman’s and HSBC Chairman’s approach – similar messages in 2005 to defend record profits in both organisations to hostile media. Each Chairman adopted a simple, powerful and compelling message designed to appeal to every audience and market. Pharma industry has not managed this effectively (yet) – a surprise since nature of pharma should make task relatively easy.

    Result: better media coverage, better corporate image, better government relations, better talent recruitment and retention, better morale and productivity.
    Content of message: How pharmeceutical industry is helping create a better kind of world for individuals, families, communities, wider humanity. Urgent need for new treatments (mainly to treat older people), and how pensioners and pension funds are providing 75% of the investment needed to develop them. How pharmaceutical industry not only is touching millions of lives, but is also providing financial security for millions of pensioners, by investing wisely in innovative, affordable treatments that really make a difference. Product pipeline, outlook etc.

    Need a world-class pharmaceutical industry keynote speaker? Phone Patrick Dixon now or email.

    Slides / keynote presentations on

    Future of the pharmaceutical industry – for Wyeth (2008)

    Future of the pharmaceutical industry – for International Conference for Pharmaceutical Medicine (ICPM 2008)

    6 Tips to Rewriting Your Resume for Pharmaceutical Sales #big #pharma #companies

    #pharma resumes


    6 Tips to Rewriting Your Resume for Pharmaceutical Sales

    Pharmaceutical sales is an immensely popular industry in the U.S. and abroad, both because of the excellent earning potential and the fact that sales reps often have the opportunity to create their own schedule rather than being tied down nine-to-five in an office. There is also a lot of growth in the field, from sales representative to district manager to regional or territory manager and finally to corporate roles.

    With that in mind, it s no surprise that hundreds, even thousands, of resumes are received each month by pharmaceutical recruiters and the HR offices of pharmaceutical companies.

    So how is someone supposed to stand out?

    Well, the first thing is experience. If you have a strong background in sales, especially pharmaceutical sales or medical sales, you ve got an edge — maybe. Like everything else, there isn’t one hard rule on the ideal pharmaceutical sales candidate. For example, some companies prefer candidates without any industry experience — at least for those more entry-level positions — because they prefer new hires go through the company’s training program to learn their way.

    But what about those job seekers who don t come from one of the top two backgrounds? In those cases, it s essential to highlight the pertinent, transferable skills you do have in such a way so that you attract the attention of hiring professionals. Let s look at how you can do this.

    1. What’s on The Pharmaceuticals’ Wish List? This step involves identifying what skills and backgrounds companies look for in potential pharmaceutical sales reps and determining which ones you have, so that you can highlight them in your resume. Examples might be previous sales experience, account management, event management, communications, psychology, and customer service. If you are a recent college graduate, finding your transferable skills might be harder, so look beyond the classroom. Were you involved in fundraising activities? Work a retail job in the summer? Complete advanced projects for a particular class?

    You might be wondering how some of these things are related to sales, but if you think carefully, you ll see that transferable skills are not always obvious but they are important. For instance, a background in psychology prepares a person for using subtle phrases and strategies to mold their opinion on something, such as a product, or to spot non-verbal clues to how a person is feeling about a product. Event management can be important because many pharmaceutical sales roles involve arranging meetings, lectures, and presentations with medical staff. Fund raising is a type of sales that is even harder to do than most – you re trying to get people to give you money and get nothing in return!

    2. Turning Your Experience into Keywords. Now that you ve identified your skills, it s time to craft the proper phrasing in the resume. It s essential that you incorporate industry-specific keywords when you describe your experience and skills. What are some important keywords for pharmaceutical sales? Sales and Marketing, Account Management, Territory Management, Revenue Growth, Relationship Management, Customer Service, and Presentations, just to name a few. You can find plenty of the most common ones just by reading a handful of pharmaceutical sales rep job descriptions. But building keywords into your resume goes beyond the obvious. Sales is all about personality, so think about the attributes a good sales person has. They are aggressive without being obnoxious, they see ‘nos’ as opportunities, they are experts at the products they sell, and they are personable and friendly. While you don t want to focus too much on personality in a resume, you can usually sneak in some soft skills:

    Aggressive but friendly Sales Professional with consistent history of penetrating and acquiring accounts.

    Even if you don t have pharmaceutical or medical sales experience, that is a sentence that will appeal to just about any hiring manager when they see it at the top of your resume.

    3. Branding Statements Taglines. A one or two-line branding statement will do wonders for your resume, and can help set you apart from other candidates. A good branding statement can be crafted by taking your 15-second elevator pitch (you do have one for your interview, don t you?) and reworking it so that it gives someone a great idea of who you are. Remember our sample keyword sentence from earlier?

    Aggressive but friendly Sales Professional with consistent history of penetrating and acquiring accounts.

    That s an excellent branding statement for a sales professional.

    Following the branding statement, it s always a good idea to have a tag line. This is a related sentence or group of words that demonstrates the value you have to offer. Look at this example:

    Award-winning Sales Representative – Top 5% Producer and consistent President s Club Winner

    The branding statement and tag line also serve as excellent segues into your career summary.

    4. Include the Right Information. This article isn t about the specifics of resume format. If you are looking to shape a resume for the pharmaceutical sector, you should already have a good idea of the different parts of a resume – summary, experience, education, training, etc. What we want to do now is remind you to include special information that you might have normally left off your resume. Do you have any previous experience in the healthcare field? Maybe you took some medical coding courses-add them to your training section. Perhaps in high school or college you volunteered at a hospital – put it in community service. In college, did you take some biology classes? Mention those in your education section. Anything you can add that is relevant to the pharmaceutical industry is going to help you. The same goes for individuals who might be coming from a healthcare background but don t have any sales experience. Did you take business courses in college or some sales training seminars earlier in your career? When appropriate, add them into the resume!

    Another thing is to make sure you don t take anything for granted. Too often I see people put this in their education section:

    Biology, College Name

    To a reader, that means nothing. Did you take one biology course? Do you have an Associate s Degree? A Bachelor s? The resume isn t the place for hiding information or being vague. Here is how the education section should look:

    Bachelor s of Science in Biology, School XYZ

    Course work in Biology, School XYZ, including Anatomy, Advanced Biology, and Biochemistry.

    Most pharmaceutical companies want their candidates to hold at least a Bachelor s; maybe others are not as strict. However, all of them value education and training, so be sure not to leave something off the resume that could help you.

    5. Tell Your Story Correctly. Pharmaceutical companies and recruiters prefer to see not only what you have done, but how you achieved it. Some people make the mistake of only including half the information in their job descriptions; either they omit their achievements or they fail to show how they achieved their results. When you re writing your resume, be sure to use a Situation/Action/Result style to tell each story. This means describing the problem, showing the action you took, and listing the result.

    In order to achieve sales growth for new product, developed multiple sales strategies that led to 18% market penetration six weeks ahead of projected timeline.

    The situation was to grow the product, the action was to develop sales strategies, and the result was 18% market penetration. Pharmaceutical companies are very results-driven, so including as many quantifiable results as you can on the resume will be a big help in terms of getting you more interviews.

    6. Review Your Resume. This is critical. After the resume is written, do not send it out to anyone until you and at least two other people (preferably someone with superior grammar and spelling skills) has looked it over. Remember, you are up against a lot of competition. Even a couple of typos, grammatical errors, spelling mistakes, or punctuation mistakes can mean the difference between getting an interview or having your resume end up in the trash.

    Also important is providing complete contact information (omitting your email address or phone number is a major red flag in HR offices).

    With these tips in mind, rebuilding your resume for pharmaceutical sales positions will not only be possible, but also effective.

    The Future of the Pharmaceutical Industry is in Emerging Markets – Pharmaceutical Compliance Monitor #pharmajob

    #future of pharmaceutical industry


    The Future of the Pharmaceutical Industry is in Emerging Markets

    When growth at home slows, smart companies expand abroad.

    Stagnation suffocates a company’s growth, so when profits start to level out after years of growth, smart companies immediately begin to scour the globe for new sources of revenue to move their organizations back into a more profitable position. For the pharmaceutical industry, expanding into emerging markets is inevitable and will prove to be a critical step in the industry’s evolution, despite initial growing pains.

    Let’s take a step back and look at the commonly accepted business model for pharmaceutical companies in a mature economy, such as the U.S. market. A pharmaceutical company establishes a fully integrated system including the research and development processes all the way to the finished goods facilities owned by the same company. The up- front investment is large, but controlling all assets in the process has traditionally served as a reliable model in the long run.

    Fast-forward to the 2012 patent cliff with the overwhelming volume of patent expirations and what seemed to often be insurmountable regulatory roadblocks that put a hard stop on the promise of growth in the US market. From 2002 – 2012, the value lost by products going off patent far exceeded the value created by new products entering the market creating a disconcerting financial situation for many.

    In light of that, pharmaceutical companies began looking to the promise of growth abroad in the BRICs (Brazil, Russia, India, China). These countries comprise the top tier of emerging markets in the world because they are projected to be the most economically stable and with the likelihood of becoming similar to the US market, in time. As their economies matured, the most prevalent health conditions in the BRICs began to mirror those in the developed countries, such as the US. Issues such as chronic disease, diabetes, and obesity are becoming more prevalent as the middle class grows and life expectancies increase. This changed need opens a whole new host of consumers for pharmaceutical treatments that have traditionally been marketed to Western patients.

    From purely a financial perspective, the strategic decision to move to the BRICs was well substantiated, with over 70 percent of the world living in developing or emerging markets, many of these nations of which required products to treat the influx of new medical disorders they now confronted. It’s daunting to imagine the potential new customer base and endless opportunities for growth.

    Proceed With Caution

    There have been growing pains, which should be expected. Despite the enticing financial incentives in these countries, many top pharmaceutical companies have already lost substantial revenue from seeking to operate in these emerging markets without proper risk assessments and planning prior to implementation. This could be due to the fact that the supply chain operations, manufacturing processes, and regulatory requirements are vastly different from that of the Western world.

    With a primarily out-of-pocket payment system for healthcare services due to the underdeveloped nature of emerging market health infrastructure, pharmaceutical companies stand to both improve the standard of living of patients in the BRICs while also expanding their company’s global reach and customer base. Providing the expanding middle class with high-margin generics from Western brands is the hallmark of this sort of expansion. While it seems to be a simple solution, the key to success involves significant strategy rather than a “one size fits all” approach.

    Several companies have successfully implemented programs in the BRIC markets, but those case studies all involved substantial groundwork with the populations and rigorous training of staff.

    The key to facilitating a successful pharmaceutical expansion to BRIC countries is for the organization to accept that every emerging market is different and that the landscape of the government, regulatory, and policy structure of the country and more specifically, the region, where the company seeks to expand must be audited. There is no standard recipe for market expansion, as each requires unique knowledge of the current infrastructure and technologies available. Like always, the devil is in the details.

    The BRICs have been implementing the necessary strategies to further develop their healthcare sectors, but their work is still far from over. Government-influenced growth coupled with the growing middle class, creates a need for increased public engagement and focused efforts on the specific needs of the population group. Pharmaceutical companies must develop, manufacture, and distribute drugs that fit the target audience and are affordable to consumers in that particular market.

    Prior to creating an operation in an emerging market, companies must conduct detailed research to identify market segments within the country with proper adaptation to buying patterns, education needs, training, and threshold for purchase. Often, healthcare infrastructure is not well established, creating a disparity between cost of the drug and ability to pay. Understanding the needs and education required to implement change are a critical foundation for ensuring that demand for a product will exist in these volatile environments.

    Companies must choose their population, select their focus areas, and then provide the absolute best product for an affordable price. Simply importing Western medicine that is unaffordable to the general community will not prove an effective or economically sound solution.

    Above all, education is key. In developing countries, access to inexpensive, generic drugs is critical to many patients. Pharmaceutical companies have the opportunity to improve quality of life for patients while also growing their bottom line. If a company plans to enter the market, a disease management program must be implemented to help ensure the both physicians and patients understand their condition and why a particular medication is necessary to treat it.

    For example, submarkets within a country can be identified as a customer cluster with a specific health need. If the customer cluster does not understand the need for medication or treatment, the pharmaceutical company should then focus on the needs of these consumers by providing educational materials and training to teach both physicians and patients how to use the medication, this practice promotes disease prevention while increasing healthcare consumption within the sub market.

    With pharmaceutical exports from India totaling $15 billion in the 2014 fiscal year, the opportunity for success in emerging markets is real, as long as companies understand that growth in these countries have proven to be more complicated than originally expected and take the appropriate measures to ensure success. The combined effect of the 2012 patent cliff in the US, limited healthcare systems in the BRIC, growing middle class in the BRIC, and chronic disease becoming a growing problem in developing countries led to an increased need for drugs in these expanding markets at the same time US Big Pharma needed another avenue for expansion.

    Not all expansion attempts have been immediately successful, but the consistent theme seems to be that through singular, strategic approaches based on a thorough population analysis, patient and physician education, and therapeutic niche, emerging market offer the best long-term growth opportunity for companies willing to put the work in.

    Purdue pharmaceuticals #noel #pharma

    #purdue pharmaceuticals



    A culture of innovation and making a difference

    Purdue Pharma Canada is one of the country’s leading pharmaceutical companies. As part of our mission we work to advance healthcare and make patients and healthcare professionals our focus.

    We provide long-acting analgesics, medications for the treatment of attention deficit hyperactivity disorder (ADHD), gastrointestinal disorders, and other products that patients and health professionals depend upon. We also assist patients in disease management and further the professional development of healthcare professionals through comprehensive educational programs.

    pronosticuri fotbal azi ponturi pariuri sportive

    Research and Development has always been an integral component of Purdue Pharma Canada’s operations, and we are committed to significant increases in R D activities.

    Purdue Pharma Canada is a member of Canada’s Research-Based Pharmaceutical Companies (Rx D)

    Copyright May 2012 Purdue Pharma Canada | Policies and Legal | Contact Us | 1-800-387-5349

    Buprenorphine Pipeline #capricorn #pharma

    #perdue pharma


    The National Alliance of Advocates
    for Buprenorphine Treatment

    Buprenorphine (Suboxone . Subutex 3. Zubsolv 4. Bunavail 5. Probuphine 6 ) is an opioid medication used to treat opioid addiction in the privacy of a physician’s office. 1 Buprenorphine can be dispensed for take-home use, by prescription. 1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids. 2

    Buprenorphine Pipeline

    Timeline of buprenorphine products past, present, and future

    September, 2013

    Orexo receives FDA approval for Zubsolv (buprenorphine/naloxone sublingual tablets) launched in September 2013

    November, 2014

    UPDATE: In pharmacies now 11/2014 – press release BioDelivery Sciences International, Inc. files NDA with the FDA for BUNAVAIL (Bup/Nx buccal soluble film) 7/31/13.

    Probuphine delayed 1-2 years

    Titan Pharmaceuticals, Inc. – 3/21/13 – FDA Advisory Committee recommends approval of Probuphine (long-acting, subdermal buprenorphine implant)
    UPDATE – April 30, 2013 FDA says NO!

    February 25, 2013

    Actavis receives FDA approval 2/0.5mg and 8/2mg sublingual buprenorphine/naloxone tablets (GnrBupNx2 )

    February 25, 2013

    Amneal Pharmaceuticals receives FDA approval 2/0.5mg and 8/2mg sublingual buprenorphine/naloxone tablets (GnrBupNx1 )

    August 20, 2012

    Reckitt Benckiser Pharmaceuticals Inc. receives FDA approval for Suboxone Film 4/1mg and 12/4mg (sublingual buprenorphine/naloxone)

    September 24, 2010

    Hi-Tech Pharmacal Co. receives FDA approval for sublingual buprenorphine tablet (GnrBup3 )

    August 31, 2010

    Reckitt Benckiser Pharmaceuticals Inc. receives FDA approval for Suboxone Film 2/0.5mg and 8/4mg (sublingual buprenorphine/naloxone)

    July 7, 2010

    Perdue Pharma L.P. receives FDA approval for Butrans 7-day transdermal buprenorphine patch

    May 25, 2010

    Teva Pharmaceuticals USA Inc. receives FDA approval for sublingual buprenorphine tablet (GnrBup2 )

    November 1, 2009

    Midlothian Laboratories receives FDA approval for sublingual buprenorphine tablet (GnrBup4 )

    October 8, 2009

    Roxane Laboratories receives FDA approval for sublingual buprenorphine tablet (GnrBup1 )

    October 8, 2009

    Reckitt Benckiser Pharmaceuticals Inc.’s Orphan Drug Marketing Exclusivity for Suboxone and Subutex expires

    December 29, 2006

    DATA-2000 amended to allow 100 patients per physician certified for more than one year

    August 2, 2005

    DATA-2000 amended to allow 30 patients per physician in group practices – instead of 30 per practice

    October 8, 2002

    Reckitt Benckiser Pharmaceuticals Inc. receives FDA approval for Suboxone (sublingual buprenorphine/ naloxone) and Subutex (sublingual buprenorphine)

    June 30, 1985

    Reckitt Benckiser Pharmaceuticals Inc. receives FDA approval for Buprenex (0.3 mg/ml IM injectable buprenorphine)

    March 18, 1969

    Patent #3,433,791 issued for buprenorphine

    This page was last modified on. 11/09/2014

    The Purpose of Buprenorphine Treatment:

    To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. – explain –



    The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

    • Educate the public about the disease of opioid addiction and the buprenorphine treatment option.
    • Help reduce the stigma and discrimination associated with patients with addiction disorders.
    • Serve as a conduit connecting patients in need of treatment to buprenorphine treatment providers.
    1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
    2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
    3. Subutex Discontinued in the US market in late 2011.
    4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
    5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
    6. Probuphine FDA approved 5/26/2016 – FDA Probuphine press release

    Teva to buy Barr Pharma for more than $7b #pharmaceutical #companies #in #orange #county

    #barr pharma


    from the September 2008 issue

    Teva to buy Barr Pharma for more than $7b.

    Teva Pharmaceutical confirmed its purchase of rival generic drugmaker Barr Pharmaceuticals for nearly $7.5 billion in a move that will boost Teva’s dominance as the world’s largest generic drugmaker.

    The deal continues consolidation of the generic-drug sector, driven by growth prospects as governments and other payers turn to the lower-priced medications and by the impending expiration of brand-name drug patents worth billions of dollars a year.

    Israel-based Teva Pharmaceutical Industries Ltd. said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc. the world’s No. 4 generic drug maker, will also expand its presence in U.S. and other key markets, from Russia to Eastern and Central Europe. Analysts called the deal a great comination for both companies, and Barr shares jumped by double digits on the news.

    “This was the 12th attempt to acquire Barr, and the third by Teva,” Barr’s chief executive, Bruce Downey, told analysts during a conference call. “This is the right price, the right time and the right opportunity.” Barr shareholders will receive $39.90 in cash and 0.6272 of a Teva American Depositary Receipt for each share they own, a total of $66.50 per share. Teva also is offering to assume $1.5 billion of Barr’s debt.

    Barr shares finished at $46.82 before reports a deal was in the works sent the stock up 22 percent.

    The deal is expected to close at the end of this year. Teva said it should bring $300 million in annual savings within three years and add to profits within a year.

    Shlomo Yanai, Teva’s CEO, said the two companies have minimal overlap in products and that Barr would add to his company’s products and research pipeline, particularly in women’s health.

    “I cannot imagine a company that could be a better fit with Teva, our business, our people, our values,” Yanai said. At the end of july trv nnounced its finncial results. Teva Pits second-quarter profit rose, helped by strong North American sales of generics and its branded drugs.

    Quarterly net income increased 5 percent to $539 million, or 65 cents per share, compared with $515 million, or 63 cents per share, a year earlier.

    Net sales at the Israel-based company rose 18 percent to $2.82 billion.

    Analysts on average expected Teva — which earlier this month said it would buy smaller rival Barr Pharmaceuticals

    The combination is part of a trend toward globalization over the past five years, with U.S. and foreign generic drugmakers expanding into each others’ territory through increased marketing, new products or acquisitions, said Doug Long, a generics analyst at health data firm IMS Health.

    In addition, drugs with sales exceeding $54 billion a year are set to lose patent protection from 2008 through 2012, according to prescription benefit manager Medco Health Solutions.

    Last month, Japanese pharmaceutical company Daiichi Sankyo Co. agreed to pay more than $4 billion for a controlling stake in Indian generic drugmaker Ranbaxy Laboratories. Ranbaxy battled last fall for the generics business of Germany’s Merck KGaA before losing to generic maker Mylan Inc. And Barr bought Croatian drugmaker Pliva d.d. in 2006, outbidding Iceland’s Actavis Group. Cowen & Co. analyst Ken Cacciatore called the deal “a very positive strategic transaction” and said Barr could complement Teva’s future efforts to produce generic versions of biologics, or drugs made from living cells and tissues.

    Reprinted from the Israel High-Tech & Investment Report September 2008

    Click HERE to request further information.
    Click HERE to go BACK .

    Theravance Biopharma: About Us #elixir #pharma



    Winning Together

    Theravance Biopharma is a place for advanced thinkers, people who thrive on applying insight and innovation to energize scientific discovery.

    Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness.

    Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S. Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop GI-targeted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.

    In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma.

    Theravance Biopharma Ireland, Ltd
    Fitzwilliam Hall, Fitzwilliam Place
    Dublin-2, Ireland
    +353 (0)1 539 4800

    Theravance Biopharma U.S. Inc.
    901 Gateway Boulevard
    South San Francisco, CA 94080
    Local: 650-808-6000
    Toll-free: 844-ASK-TBPH (275-8274)

    2016 Theravance Biopharma. All rights reserved. THERAVANCE, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE and VIBATIV are trademarks and/or registered trademarks of the Theravance Biopharma group of companies. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. Terms Of Use | Privacy Policy

    Form content here please 🙂

    Pharmaceuticals industry #french #pharmaceutical #companies

    #pharmaceuticals industry


    Pharmaceuticals industry

    Belgium is a world leader in the pharmaceuticals industry. The latter is a key sector in terms of jobs: it employs almost 30,000 workers in Belgium and this figure is growing year on year. Pharmaceuticals account for over 10% of Belgium’s total exports.

    Accordingly, both the pharmaceuticals industry and the Belgian government are investing heavily in developing this sector even further and major drives are under way to promote innovation and R D.

    Private investment

    Every year, the pharmaceuticals industry ploughs over €1.5 billion into R D. This represents 40% of all private investment in R D in Belgium, double the European average.

    Government support

    The government also supports the pharmaceuticals industry – and R D in general – via a range of tax incentives and discounts and by offering assistance in hiring qualified researchers. A consultation platform to forge links between the pharmaceuticals industry and the government has also been set up to improve public health and boost innovation and employment.

    More info

    UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #pharmaceutical #industry #report

    #sankyo pharma


    UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ

    Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April.

    The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That drug’s $2.6 billion in annual sales accounted for 27% of Daiichi’s sales last fiscal year.

    Now, the latest belt-tightening is hitting the U.S. commercial team. “Following a thorough review of our business, we have made the decision to reorganize our operations, which includes the difficult step of select workforce reductions,” spokeswoman Kimberley Wix told FiercePharma .

    “This is an unfortunate, but necessary step towards addressing near-term challenges and positioning ourselves for long-term health and success.” These cuts are limited to the commercial operations, with R D and other functions unaffected.

    Though the drugmaker has some newer products to market, it will take time to rebuild Daiichi’s top line that way. Its new anticoagulant Savaysa entered a warfarin alternative market already crowded with blockbusters–including Johnson Johnson ($JNJ) and Bayer’s Xarelto–and comes with a black-box warning its rivals don’t have.

    And so far, M A hasn’t paid off. The Tokyo-based company’s buyout of Indian generics maker Ranbaxy Laboratories was all but doomed by manufacturing problems that surfaced soon after the deal closed. The buyout failed so spectacularly that executives in Japan took a pay cut, and Daiichi bailed out last year, agreeing to sell Ranbaxy to fellow Indian drugmaker Sun Pharma. Other deals, such as its $410 million buyout of San Diego biotech Ambit, are R D-focused, and won’t deliver near-term sales.

    The home-office cuts will fall mostly on the sales organization, according to sources close to the situation. Follow-up layoffs are also on their way. Sales reps in the field are set to find out their fate in mid-April, with cuts of 30% or more expected, sources said. Wix said she could not provide a percentage, but “we expect the number of field sales representatives being displaced to be limited.”

    Pharma sales forces have suffered waves of job cuts in recent years as big blockbusters fell off patent, many replaced by specialty medications. Those drugs tend to be prescribed by specialists, rather than primary-care doctors, which means fewer sales reps on the street.

    Plus, as insurers and pharmacy benefits managers grow increasingly demanding, pharma companies have deployed more payer-focused sales teams. The last thing drugmakers want is for their new meds to end up excluded from top formularies, or tagged with top-tier, high-copay, prior-authorization status. Hospital-focused reps have also grown in number, as hospital systems snap up physician practices and higher-ups make more prescribing decisions.

    Daiichi is one of the companies relying more on “key account managers” rather than front-line sales reps, according to a recent article in Medical Marketing Media. The company now has 10 of those account managers marketing meds to 70 health systems.

    The numbers on Daiichi’s sales rep cuts are still in the works, Wix said. “Final decisions regarding the field sales staff will be made by mid-April,” she said, noting that the company has “taken many steps to support colleagues of ours who are being displaced.”

    Special Reports: Top 10 largest pharma layoffs of 2013

    Editor’s note: This story was updated with more specific details about the ongoing job cuts, provided by Daiichi Sankyo.

    Bilcare Company partners with pharmaceutical and healthcare industry across US, India, Europe and Singapore #pharma

    #pharma packaging solutions


    About Bilcare

    Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. We endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.

    Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.

    Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.
    Bilcare Technologies provides track and trace, authentication and Anti-counterfeit (nCID – nonclonableID) solutions for product people ID authentication and security.

    Our other packaging films solutions cater to various industries which includes ID Card industry, Specialty Films Applications and Food packaging.

    Bilcare s philosophy involves working closely with our customers to develop packaging solutions addressing mainly the core challenges of the pharmaceutical companies –commonly known in Bilcare as 5 Cs viz. Compliance – directions of dosage administration, Counterfeiting – deterring piracy and counterfeit in medicines packaging; Communication – differentiating and brand recall strategies; Convenience – smart and easy to carry, dispensing; Child Resistant Packaging – to avoid accidental misuse by children). These comprehensive Innovative Packaging Solutions backed with technology helps our Pharma customers to secure and grow their brand in the global market.

    Bilcare s multiple manufacturing and R D facilities on Innovative Pharma Packaging Solutions are spread across in Europe, USA and Asia. These facilities together with our global sales force makes us reach and serve our customers to over 100 countries with our wide range products and services.

    Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy s, GlaxoSmithKline, Johnson Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 1000 customers in over 100 countries worldwide.

    Over the years, our research activities have enhanced our range of proprietary products and services. This has resulted in creating a large patent portfolio with distinctive solutions. As of March 31, 2014 Bilcare has filed for over 198 patents worldwide and are at various stages of granting of which 21 new patent filled on 2014.

    Bilcare is an organization made up of motivated people, who believe in going that extra mile to spread excellence and joy.

    Sankyo pharma #future #of #pharmaceutical #industry

    #sankyo pharma



    Daiichi Sankyo Co. Ltd
    3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo
    103-8426 Japan

    What are the top job boards in the pharmaceutical #research #pharma

    #biotech pharma jobs


    What are the top job boards in the pharmaceutical/biotech space?

    Great question – In my opinion one of the best tools there is when looking for a job in the pharmaceutical/biotech space is Linkedin.

    Creating a profile on Linkedin is essentially your chance to showcase your strengths, thus encouraging not only the right people, but also the right opportunities to come to you.

    Here are a few tips to help you create a great Linkedin profile:

    1. Upload a picture: Make this a professional headshot – nothing inappropriate!

    2. Summary: Write this in the mindset of a prospective employer. It might be best to write this in Microsoft Word first so that you can easily cut, paste and edit – this might also help you to organize your thoughts. When writing the summary it might be useful for you to keep in mind the following: If someone were introducing you to another person, what would you want this person to know about you and why? Mention the following:

    · Who are you currently? What company do you work for and what makes them special?

    · What have you accomplished? Pick 3-5 things – they can be regarding jobs, education, and honours.

    · Goals that you would like to achieve in the future.

    · In the specialties section, list any trade or skill which you think you have learnt with some ability.

    3. Descriptions about past jobs: This will help viewers understand where you come from in more depth than your summary will.

    · Treat this as your online CV – the easiest way to complete this section is to cut and paste sections of your CV, to ensure it includes a good number of keywords.

    · Use bullet points.

    · Include any contract work, non-profit assignments, or any other work experience.

    4. Education: Start at Secondary and Undergraduate education. You can also list vocational education or any courses you have attended.

    5. Have more than 30 contacts: This shows viewers of your profile that you are professional and that you know how to network. Also, by increasing the number of people you are connected to, you increase the likelihood of people viewing your profile.

    6. Recommendations: Sometimes, what other people write about you is more valuable that what you write about yourself. A good way to get recommendations is to recommend other people. Recommendations don’t necessarily have to come from people who work above you.

    7. Customise your URL: This will help your profile rank higher on Google and make it easier for people to find you. Your LinkedIn URL should appear as “ ourfullname .” To do this, go to your profile and click “edit” and then next to where it says “public profile,” click “edit” again. At the top, you’ll want to click “edit” one more time next to “your public profile URL,” and then type in your full name, without spacing, and click “set address.” If the unique URL is taken, then try using a period between your first and last name or use your middle initial.

    · Make sure your profile is completely grammatically correct and that each section is complete.

    · Flood your profile with lots of keywords relevant to the pharma industry you work in.

    · Frequently update your status with useful content, where possible including a link back to the company website.

    · Actively comment on Linked In discussion forums – this gives you the opportunity to demonstrate your skills and knowledge of relevant industries. These discussion forums are essentially a 24/7 networking event.

    I hope you have found this useful. o)

    SPI Pharma Careers and Employment #star #pharma

    #spi pharma


    About SPI Pharma

    Think you re the best thing since sliced bread? Associated British Foods (ABF) is sliced bread. ABF, which introduced sliced bread in the UK during the 1930s, makes and markets baked goods under the Allinson and Tip Top brands. Its grocery products, which account for some one-third of sales, include household staples Karo syrup, Argo corn starch, Kingsmill more. bread, Silver Spoon sugar, and Twinings tea. In the US, it owns Fleischmanns Yeast and ingredient and spice maker ACH. Other divisions churn out sugar, pharmaceutical ingredients, specialty oils, and animal feed. Beyond food, ABF owns Primark, a retail clothing chain in the UK, and parts of Europe. ABF s activities span nearly 45 countries worldwide.

    ABF benefits from a diversified basketful of international name brands. More than 50% of the company s sales and about 45% of its operating profits are generated outside of the UK. Grocery operations provide a slow-growth platform from which to pursue higher-growth yet more volatile commodity markets, such as agriculture and sugar.

    Despite a difficult global economy, ABF has managed to shore up its performance. Following a two-year decline, in 2010 year-over-year earnings (US currency) climbed more than 50%, slipping slightly in 2011, on a modest acceleration in sales. Results were driven by more than a two-fold increase in demand from the Asia/Pacific region, which helped offset a sharp decline in the Americas.

    ABF s cash position, which bounced up in 2010 and down the next year, reflects a handful of capital investments. Among them, the company has funded a new meat factory in Australia, and launched Vivergo Fuels Ltd. The UK wheat bioethanol plant, operational in 2012, is a joint venture among ABF, BP, and DuPont, which produces bio-fuel and animal feed.

    Sugar prices, which marked a 30-year high during most of 2011, have also buoyed recent earnings. ABF s sugar business (representing about 20% of sales), took off in 2009 with the acquisition of Azucarera Ebro, a beet sugar producer owned by Ebro Puleva. The takeover has strengthened ABF s business infrastructure; previously, ABF orchestrated a long-term agreement for its African sugar processor, Illovo, to supply Azucarera Ebro with raw cane sugar. In addition, Azucarera produces ethanol and animal feed. ABF bolsters operations further with a handful of cane sugar mills and beet sugar factories in China.

    Elsewhere, ABF is continuing to invest in Primark as it faces off lower consumer spending coupled with higher unemployment. Over the last 10 years, the clothing retailer has doubled its store count, expanding to generate more than one-quarter of the company s sales. Some 220 stores primarily in the UK, but with a growing presence in Western Europe, cater the latest fashion trends to the under 35-year-old woman. During 2011, retail operating profits slumped some 9% on more than a 10% uptick in sales over the prior year. ABF cited its decision to absorb the costs associated with increased cotton prices and higher UK taxes in order to preserve its customer base.

    ABF s future, in large part, looks to its past. It is one of the UK s biggest family owned businesses. Founded in 1935 by W. Garfield Weston, his great-grandson CEO George Weston, and the Weston family own approximately 55% of ABF. less


    SPI Pharma

    Overall Rating

    Editorial: State s case against Perdue Pharma deserves full hearing #alembic #pharma

    #perdue pharma


    Editorial: State’s case against Perdue Pharma deserves full hearing

    While the prescription pain pill epidemic that plagued this region for nearly a decade has been replaced by a heroin epidemic, a lawsuit the state filed against Perdue Pharma, the marker of OxyContin, is still pending. Ironically, an unfavorable ruling against the company regarding a deadline it missed could cost Perdue Pharma more than $1 billion.

    In a suit dating to when now Speaker of the House Greg Stumbo, D-Prestonsburg, was attorney general, Kentucky claims Purdue Pharma misrepresented OxyContin, resulting in a wave of addiction and increased medical costs across the state. But before the trial can start, both sides must file “admissions” so the court can determine a set of facts that are not in dispute.

    Kentucky officials filed theirs, which included claims Purdue Pharma lied about the addictiveness of the drug to doctors, who then overprescribed it to an unwitting population of poor people in Eastern Kentucky. When Purdue Pharma did not respond, Pike Circuit Judge Steven Combs ruled those claims were admissible in court. That cleared the way for the state to potentially win the lawsuit, with the only question being how much Purdue Pharma would have to pay.

    “I always thought if we ever got it to a court of law, a billion dollars wouldn’t touch it,” said Stumbo, who stepped down as attorney general when his term expired in December of 2007.

    Combs’ decision surprised Purdue Pharma officials. When the state filed its claims in 2007, the company had 45 days to respond, but in the middle of that window, Purdue Pharma moved the case to federal court, which put the state-court action on hold.

    More than five years later, the federal court sent the case back to state court at the request of the Kentucky attorney general’s office. Attorney General Jack Conway’s office argues that meant the clock restarted on the original deadline for Purdue Pharma to respond to the state’s request it admit or deny damaging conduct.

    However, Purdue Pharma contends the original deadlines died when the case was transferred to federal court and the state should have had to serve new requests for admissions on the company. On Thursday, the two sides made oral arguments to the state Supreme Court on the issue.

    Purdue Pharma wants the high court to issue an order that would, in effect, strike down the admissions of liability Combs accepted. Purdue Pharma said a co-defendant in the case, Abbott Labs, also missed the deadline, yet the court allowed that company to file a response anyway. They said if the case moves forward like this, the company won’t be able to adequately defend itself and won’t be able to get information from Kentucky officials about the state’s role in the epidemic of prescription painkiller abuse.

    “The commonwealth is going to be able to use (these admissions) as a sword and as a shield to keep us from finding the information that we need to develop a full record,” attorney Daniel Danford said.

    Danford argued Combs’ ruling was incorrect and letting it stand would cause irreparable damage to the company.

    On the other hand, striking down Combs’ order would just put the case back on its original path and not hurt the state, Danford said.

    Conway’s office contends the state lawsuit was suspended when it was transferred to federal court, then restarted when it came back. That’s the way courts have handled cases like this going back 50 years, and making an exception for Purdue Pharma will result in a flood of similar requests from other litigants who miss deadlines, the state contends.

    “Purdue Pharma could care less about the merits of this case,” Assistant Attorney General Mitchel Denham said. “They are a multi-billion-dollar company here asking this court for special accommodations and to change the rules because they did not follow the clear and simple rules.”

    Conway’s office also argues the company would have adequate appeal remedies if the high court upholds the decision to let the admissions of liability be used against the company.

    The state argues it already has been harmed by how much time Purdue Pharma kept the case alive in federal court​.​ One key witness died, for instance.

    The company and three officers pleaded guilty in federal court in Virginia in 2007 to making misleading claims about the addiction potential of OxyContin. A judge ordered a fine of more than $630 million.

    Kentucky had joined other states in an action against Purdue Pharma, but the company offered ​the ​state only a little more than $500,000 to settle.

    The state rejected the settlement and joined Pike County in a lawsuit against the company.

    Conway, the likely Democratic nominee for governor, said last week Purdue Pharma is trying to escape the consequences of fueling a deadly epidemic of drug abuse. “We’re just holding their feet to the fire,” he said.

    There is no question Purdue Pharma profited from the pain pill epidemic in this region, but did the drug manufacturer fuel the pain pill epidemic by failing to warn physicians prescribing OxyContin of the highly addictive nature of the pain medication and discourage overprescribing? Were patients warned of the dire dangers of failing to take the drug exactly as prescribed?

    Because of the extreme damage caused by the prescription drug epidemic, both the Commonwealth and Purdue Parma deserve a full, fair and unbiased hearing in open court on the state’s claims and Purdue Pharma’s response to them.

    Because of the state’s lawsuit being transferred from state to federal court and then back to state court, it is understandable Purdue Pharma could have become confused about its deadline for filing a response. Fairness to all demands the drug manufacturer be given another date for filing a response and the suit be allowed to proceed from there. It is premature to make any judgment in this case. A full hearing is needed — and soon.

    Sign Up / Sign In

    Sign In

    Sign In

    Almost Done!

    Thank you for registering!

    Almost Done!

    Create a new password

    Create a new password

    Sign in to complete account merge

    Sun Pharma to buy Dusa for $230 million #pharma #crm

    #dusa pharma


    Sun Pharma to buy Dusa for $230 million

    Updated: Thu, Nov 08 2012. 11 43 PM IST

    Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore).

    Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday.

    The transaction has a total cash value of approximately $230 million. The transaction has been unanimously approved by the boards of directors of both companies and DUSA s board has recommended that the company s shareholders tender their shares pursuant to the tender offer, it said in a statement.

    This is the third sizeable foreign acquisition by Sun Pharma since 2008. Sun Pharma, which was founded in 1983 as a small unit in Kolkata with five drug formulations in its portfolio, has followed a strategy of making acquisitions to power future expansion while pursuing growth on its own. The company has made at least a dozen acquisitions, each time adding a different set of capabilities to its business.

    DUSA has proven technical capabilities in photodynamic skin treatments, with US Food and Drug Administration-approved manufacturing, and its business brings us an entry into dermatological treatment devices, where we see good growth opportunities, managing director Dilip Shanghvi said in the statement.

    An analyst with a foreign brokerage firm, who didn t want to be identified, noted that Sun Pharma lacked a strong enough presence in the skincare market in both domestic and foreign markets.

    The DUSA deal brings that strength for the company. However, this deal, as it seems similar to its Taro acquisition in 2009, may also face difficulties for completion as it involves share purchase from the market, said the analyst. It was a reference to Sun Pharma s purchase of Israel s Taro Pharmaceutical Industries Ltd .

    The stock purchase from the market through a tender will be subject to certain conditions, including the tender of at least a majority of DUSA s outstanding shares (assuming the exercise of all options and warrants, and vesting of restricted shares).

    Upon the completion of the tender offer, Sun Pharma will acquire all remaining stock at the same price of $8 per share through a second-step merger, subject to necessary approvals, said the Sun Pharmaceuticals statement.

    We are confident that Sun Pharma will build upon the solid foundation our organization has established in the US dermatology market, stated Robert Doman. president and chief executive officer of DUSA Pharmaceuticals.

    The adviser for the deal was Leerink Swann Llc. Reed Smith Llp acted as legal advisor to DUSA Pharmaceuticals.

    Sun Pharma, which announced its September quarter results on Thursday, posted a drop of about 47% in net profit at Rs. 320 crore.

    Profit was dented by a Rs. 583 crore one-time expense on account of a liability arising from patent litigation with US drug maker Wyeth Pharmaceuticals Inc.. a part of Pfizer Inc. Sun Pharma s sales grew 41% during the quarter to Rs. 2,683 crore.

    Wyeth Pharmaceuticals had in February sought $960 million in damages from Sun Pharma for alleged patent infringement in launching a generic version of acid reflux drug Protonix in the US.

    Sun Pharma said in its earnings statement on Thursday: The company continues to believe that it has sound reasons to disagree with the overstated claim of Wyeth, and will pursue all legal remedies including appeals as it believe the patent referred in the litigation is invalid and unenforeable.

    Sun Pharma shares fell 0.76% to Rs. 696.15 on BSE Ltd on Thursday, while the benchmark index, the Sensex, lost 0.3% to 18,846.26 points .

    First Published: Thu, Nov 08 2012. 05 54 PM IST

    SPI Pharma #nectar #pharma

    #spi pharma


    SPI Pharma

    How do SPI Pharma fit into ABF Ingredients?

    SPI Pharma are a pharmaceutical company within ABF Ingredients, with headquarters in the USA and sites in the USA, France and India.

    SPI Pharma provides innovative solutions global pharmaceutical and nutritional customers need to succeed. SPI Pharma help customers solve even the most challenging formulation problems – efficiently, cost-effectively, and with a focus on service.

    SPI Pharma is headquartered in Wilmington Delaware, USA and has manufacturing locations in New Castle Delaware, Lewis Delaware, Grand Haven Michigan, and Septemes Les Vallons, France. In addition, SPI Pharma have a research and development centre in Bangalore, India.

    As a global leader, SPI Pharma serve over 55 countries with formulation innovation, technical assistance, and troubleshooting support. Products include antacid actives, excipients, taste-masking technology, drug delivery systems for tablets, fast-dissolve technologies, and a variety of other creative offers for patient-friendly dosage formats. Focusing solely on the pharmaceutical market, ensuring best-in-class products provide exceptional quality by meeting or exceeding global regulatory requirements.

    Isis Pharma Changes – Unfortunate – Name to Avoid Confusion – Scientific American #pharma #info

    #isis pharma


    Isis Pharma Changes “Unfortunate” Name to Avoid Confusion

    The drugmaker – named after the Egyptian protector and healer goddess Isis, who was revered as a protector and healer – has been around for more than a quarter century. Credit: ManuelVelasco via iStock

    By Reuters Staff

    (Reuters) – After deliberating for most of the year, Isis Pharmaceuticals Inc said on Friday it would change its name to avoid being confused with the Islamist militant group known as ISIS.

    The biotechnology company said it would be called Ionis Pharmaceuticals Inc from Dec. 22 and also changed its stock exchange ticker symbol to IONS from ISIS .

    It’s been an ongoing discussion for most of this year , Chief Business Officer Sarah Boyce told Reuters.

    When you talk about the company you want people to immediately think about the incredible work you’re doing to deliver transformational drugs to patients. not as an unfortunate namesake.

    The Carlsbad, California-based company’s stock dropped about 4% on the first trading day after the Paris attacks, for which ISIS claimed responsibility.

    The drugmaker – named after the Egyptian protector and healer goddess Isis, who was revered as a protector and healer – has been around for more than a quarter century.

    Today it is a $7 billion company with one cholesterol drug on the market and treatments in development for a plethora of diseases, including cancer and heart conditions.

    Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific publications (many of them can be found at ). Scientific American maintains a strict policy of editorial independence in reporting developments in science to our readers.

    2016 Scientific American, a Division of Nature America, Inc.

    All Rights Reserved.

    Back to School

    Get 50% off digital subscriptions of Scientific American and Scientific American MIND!

    Tris Pharma announces launch of generic TUSSIONEX #swiss #pharma

    #tris pharma


    Tris Pharma announces launch of generic TUSSIONEX

    Published on October 1, 2015 at 8:39 AM

    Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX , an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

    Tussionex , originally approved in the early 1980 s, had no generic competition until 2010 when Tris Pharma s generic product entered the market under an exclusive distribution agreement with Par Pharmaceuticals. Under the terms of the distribution agreement, Par had the exclusive right to market Tris Pharma s hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension for a five year period ending September 30, 2015. With the conclusion of the five year term, the rights have reverted back to Tris and as of October 1, 2015, hydrocodone polistirex and chlorpheniramine polistirex ER Suspension in 115ml and 473 ml bottles (compare to Tussionex ) will be marketed and distributed by Tris Pharma s generic business.

    Unlike the original product based on 1970 s technology involving organic solvent based coating, Tris product is based on its patented and highly versatile technology, LiquiXR , which avoids the use of toxic organic solvents by employing an aqueous based coating system. Tris has pioneered the delivery of taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and film strips that are otherwise traditionally associated with immediate release.

    Manufactured at Tris U.S. Food and Drug Administration (FDA)-inspected, state-of-the-art facility in Monmouth Junction, NJ, Hydrocodone Polistirex Chlorpheniramine Polistirex 10mg/8mg ER Suspension in 115ml and 473 ml bottles (compare to Tussionex ) are now available in the U.S. through wholesalers and distributors, as well as directly to the trade. Hydrocodone Polistirex Chlorpheniramine Polistirex 10mg/8mg ER Suspension was approved by the FDA on October 1, 2010. It is distributed in accordance with FDA and U.S. Drug Enforcement Administration (DEA) regulations governing the handling of CII controlled substances.

    SOURCE Tris Pharma

    From Valeant to Horizon and Endo, Pharma Gloom Spreads – The Big Number – MoneyBeat

    #endo pharma


    From Valeant to Horizon and Endo, Pharma Gloom Spreads The Big Number

    Mar 21, 2016 8:55 am ET

    At the start of each week, MoneyBeat publishes a short column in the WSJ print edition highlighting a statistic getting traction in the markets. This week’s “big number“ is $19.67 billion, the combined decline in stock-market value of Valeant Pharmaceuticals International. Mallinckrodt PLC, Horizon Pharma PLC and Endo International PLC last week.

    Concerns about the fate of Valeant Pharmaceuticals International Inc. has investors not only fleeing Valeant s stock but also shares of companies that bear a resemblance to the Canadian pharmaceutical firm.

    Valeant s shares fell 61% last week after the Canadian drugmaker on Tuesday cut its earnings guidance and warned about a potential default on its debt due to a delayed filing. The news weighed heavily on the shares of three other pharmaceutical companies. Mallinckrodt PLC, Horizon Pharma PLC and Endo International PLC fell 21%, 25%, and 30% respectively last week. Endo, down 51% this year, is the S P s worst performer in 2016.

    Collectively, all four firms lost nearly $20 billion in stock-market value last week. Valeant shed $14.5 million of its market capitalization to end the week valued at $9.2 billion, according to FactSet. Its stock closed at $26.98 per share, falling an additional 9% Friday. Valeant has lost more than $80 billion in market cap since shares were at their peak in early August.

    Meanwhile, Endo International lost $2.8 billion in market value; Mallinckrodt $1.6 billion; and Horizon Pharma $740 million.

    Many analysts have told investors that Valeant s troubles are far worse than its rivals, yet that hasn t kept investors from selling.

    Pharma job search #contract #pharma

    #pharma job search


    278BioTech / Pharmaceuticalindustry jobs

    • West
    • Login to view salary
    • Responsibilities: Provide support for finance activities: closing, balance sheet. Responsible to maintain and reconcile general ledger. Review and perform monthly amortization of prepayment on monthly basis prior to month-end close. Assist in preparation of statutory and taxation schedules and.

    Associate Engineer (MNC / Pharmaceutical / East / 5D / Up $3.5k / GMP / Gxp Doc / )

    • East (Singapore)
    • Login to view salary
    • Our Clients A fast growing and leading pharmaceutical company of high establishment is undergoing expansion plans in the region to support the.
    • West
    • Login to view salary
    • Responsibilities: Carry out analytical testing on Finished Products and Raw Materials to support production activities, and the needs of other departments/sections such as A TG, Material Management, Procurement, and E M and to ensure timely release of FP and RM. Investigates and documents.

    Engineer, Automation

    • Global healthcare leader that offers career growth opportunities
    • Positive and collaborative work environment
    • A shared purpose in saving and improving lives around the world
    • West
    • Login to view salary
    • Under the supervision of the IPT Automation Lead, Automation Engineer is responsible for providing technical support in the field of automation.

    Medical Officer

    • West
    • Login to view salary
    • Job Summary Perform Medical Monitoring (Assess feasibility, give scientific input from start up through to close out, review protocols). Maintain.

    Medical Sales Executive

    • East
    • Login to view salary
    • Responsibilities Promoting and selling Traditional Chinese Medicine (TCM) products to Chinese medicine clinics and medical halls. Contact new or.

    Sr Software Engineer (Bioinformatics) – (5846BR)

    • Singapore – Singapore
    • Do you want to make a difference? Illumina’s mission is to improve human health by unlocking the power of the genome. If that inspires you, let’s.

    Organizational Learning Executive

    • West
    • Login to view salary
    • Responsibilities: Address training needs (functional skills and development training) Conduct Annual Training Needs Analysis with business partner to determine departmental training requirements to meet business needs. Monitor departmental training status with individual leaders on regular basis.
    • West
    • Login to view salary
    • Responsibilities: Perform studies to identify and improve existing process efficiency. Conduct process validation in coordination with Technical Services, QA, E M and other departments. Monitor and report indicator of process performance. To lead in motivating and reinforcing expected.

    Facility Security Maintenance Specialist – MNC (Medical) / North / S$2.5K to $3.1K

    • North
    • Login to view salary
    • US MNC (Medical) / North/Up to S$3.1K
      Familiar with preventive and corrective maintenance for all Security systems -CCTV, Card Access System, Door Alarm System, and etc
      12 month renewable contract
      Experience in Manufacturing Industry preferred
      Our client.

    Senior / Automation Engineer – Life Science MNC

    • East
    • Login to view salary
    • Strong hands-on experience in equipment, Jigs Fixture Factory automation and medical equipment design experience preferred.
      Opportunity to be stationed in US Plant (6- 18 months) for product transfer training
      Singaporean only
      Our client, a US Life Science.

    Quality Engineer-Software Validation (US Biomedical Manufacturing)

    • East
    • Login to view salary
    • Responsibilities: Responsible to assure that manufacturing processes comply with the product specification and regulatory government agencies requirements. Provide mechanisms for controlling the total quality and establish ways of evaluating the quality of our products. Responsible to develop.

    Pharma job #pharmaceutical #companies #in #los #angeles

    #pharma job



    Career opportunities

    Working at Algorithme Pharma allows you to demonstrate your expertise and make a difference by contributing to the continued growth and success of our organisation.

    You may join us in a variety of roles in the following departments:

    • Laboratory
    • Clinical Operations
    • Scientific and Regulatory Affaires
    • Quality Assurance
    • Project Management
    • Business Development and Marketing
    • Data Management
    • Statistics and Biometrics
    • Information Technology
    • Administration

    If you are interested in joining us, take a look at our current openings and submit your resume.

    Using this system, you can view all employment opportunities available at Algorithme Pharma, create an online profile of yourself, submit your resume, and apply for open positions. Select a job category and location to filter job openings.


    Our recruitment process is open, fair and nondiscriminatory. When a job becomes available, we:

    • Post the job on our website
    • Screen applicant profiles to determine the best potential candidates
    • Invite qualified candidates to an interview
    • Conduct interviews until the recruitment process is successful

    Algorithme Pharma prides itself on being an equal opportunity employer. Please note that only candidates who meet the profile currently being sought will be contacted.

    Company philosophy

    We strongly believe in the core values that got us where we are today:

    Every employee is encouraged to take initiative and to collaborate with others in order to get the job done right while maintaining a constructive atmosphere.

    We believe in our team members, and empower them to get personally involved in all their projects. We encourage input to gain insight into the challenges that our teams face every day in order to foresee, avoid and overcome any potential pitfalls. In this way, we foster an environment of knowledge creation and maximize our efficiency with respect to our timelines.

    We all have a common goal that touches us both as an organisation and as individuals: to be the best in our respective field. Above all, we recognize that our success is largely due to our key resource, the members of our team!

    Working environment

    We strongly believe that individuals need to balance their work and personal lives in order maximise productivity and involvement in both spheres. We recognise that harmonising these two areas is different for each individual; that is why we have implemented a varied programme to support each employee in achieving this goal.

    Our flexible work programme includes benefits such as:

    • Flexible hours
    • Personal days
    • Paid time off
    • Corporate rates for a variety of services
    • Comprehensive benefits package
    • Annual evaluation process in order to foster career pathing
    • Complete training programme adapted to each position
    • Annual employee satisfaction survey

    Journal of Medicinal Chemistry (ACS Publications) #purdue #pharmaceuticals

    #medicinal chemistry


    Iminoguanidines as Allosteric Inhibitors of the Iron-Regulated Heme Oxygenase (HemO) of Pseudomonas aeruginosa

    Pseudomonas aeruginosa “>Geoffrey A. Heinzl, Weiliang Huang, Wenbo Yu, Bennett J. Giardina, Yue Zhou, Alexander D. MacKerellJr. Angela Wilks*, and Fengtian Xue*

    Porphyromonas gingivalis -Induced Pro-inflammatory Effects by High Doses of Muramyl Dipeptide “>

    Porphyromonas gingivalis -Induced Pro-inflammatory Effects by High Doses of Muramyl Dipeptide “>

    Convergent Synthesis of Novel Muramyl Dipeptide Analogues: Inhibition of Porphyromonas gingivalis -Induced Pro-inflammatory Effects by High Doses of Muramyl Dipeptide

    Porphyromonas gingivalis -Induced Pro-inflammatory Effects by High Doses of Muramyl Dipeptide “>Bin Cai, James S. Panek*, and Salomon Amar*

    H -benzo[f ]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes “>

    H -benzo[f ]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes “>

    Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H -benzo[f ]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes

    H -benzo[f ]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes “>Shiliang Li, Hongling Xu, Shichao Cui, Fangshu Wu, Youli Zhang, Mingbo Su, Yinghui Gong, Shaobing Qiu, Qian Jiao, Chun Qin, Jiwei Shan, Ming Zhang, Jiawei Wang, Qiao Yin, Minghao Xu, Xiaofeng Liu, Rui Wang, Lili Zhu, Jia Li, and Honglin Li*

    Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells

    Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex

    Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure

    Featured Content

    Isis Pharma – Online Store #pharma #research

    #isis pharma products


    Ammonium dermatitis
    This disease is associated with the appearance of rash in the groin in infants. Although there are various causes of this dermatitis, the most common inflammation remains in direct contact. This disease occurs not only in babies using disposables, but also in adults who require their use. Parents usually wor. read more

    Warts are local growths on the skin that are caused by human papilloma virus. And since they are not contagious, is possible only one family member suffers from them. It is usually affected only part of the body – such as arms or legs. There are different types of warts. Some of them are: · P. read more

    Acanthosis nigricans
    This is a skin condition characterized by discoloration, thickening and polilavyavane skin in skin folds and darts. Most often it affects the armpits, groin and neck. No specific treatment for Acanthosis nigricans, but treating the underlying disease such as diabetes, his or overweight can help lightening of. read more

    What causes pigmentation spots ?
    Pigmentation spots may be caused by sun damage, inflammation or other skin injuries including those related to acne vulgaris people with darker Asian, Mediterranean or African skin tones are also more prone to pigmentation spots, especially if t. read more

    What does rosacea look like?
    There are several symptoms and conditions associated with rosacea. These include frequent flushing, vascular rosacea, inflammatory rosacea and several other conditions involving the skin, eyes and nose. read more

    When should a sun protection be used?
    Sun protection should be used every day if you are going to be in the sun for more than 20 minutes. They can be applied under makeup. The sun’s reflective powers are great, for examples +17% on sand and +80% on snow. Don’t reserve the use of. read more

    What causes acne ?
    The exact cause of acne is unknown, but doctors believe it results from several related factors. One important factor is an increase in hormones called androgens (male sex hormones). These increase in both boys and girls during puberty and cause. read more

    What are the symptoms of pigmentation deficiency ?
    People who develop vitiligo usually first notice white patches (depigmentation) on their skin. These patches are more commonly found on sun-exposed areas of the body, including the hands, feet, arms, face and lips. Other common areas for white p. read more

    How to Get a Job in Pharmaceutical Sales #pharma #blog

    #pharmaceutical rep


    How to get a job in pharmaceutical sales

    Does a job with a good salary, a company car, a flexible schedule, generous bonuses and no boss breathing down your neck sound like a dream come true?

    It s a reality for pharmaceutical company representatives. But the work isn t pure glamour. It s also intense, highly competitive and sometimes frustrating. Insiders say it s difficult to get your foot in the door with a drug company, and that it s challenging to excel once you ve landed that first sales job.

    Do you have what it takes to make it in the field? A long-time pharmaceutical sales representative and a new hire offer some of the keys to finding — and keeping — a job in the industry.

    Sell Yourself Shamelessly

    Before you can start selling for your company, you have to sell yourself to potential employers. That can be tough, considering the level of interest in pharmaceutical sales. For every opening, we get a minimum of 150 applicants, says Corey Nahman, who has more than 25 years of experience in the pharmaceutical industry. He also maintains a Web site for pharma sales reps.

    The best way to set yourself apart is through networking. Nahman says. Companies advertise only those jobs they can t fill by word of mouth, he says. There are 58,000 drug salespeople in the country, he explains. So, chances are your friend s friend or your neighbor s friend is a pharmaceutical rep. You should get reps business cards from your doctor and call them. Most companies offer bounties to salespeople who refer new employees, so a random rep may be willing to talk to you.

    Not for the Meek of Heart

    The process of applying for pharmaceutical sales jobs, wrangling interviews and enduring rejections offers a taste of what the actual sales rep job will be like. Pharmaceutical companies don t look for one standard profile in their sales forces. Generally, companies require sales reps to have at least a bachelor s degree, and some prefer MBAs. Employers don t necessarily require degrees in areas such as chemistry or biology, but reps must be willing to learn — and be able to master — science. An aptitude in science is a prerequisite, says Nahman, a former pharmacist. If you don t like science, this job will be a living hell.

    Some companies weigh previous marketing or healthcare-industry experience heavily, although clinical skills alone won t get you hired. The most important qualifications are people skills, such as tact and diplomacy, Nahman explains. Science can be learned, but people skills can t be learned.

    If you re lucky enough to land an interview, be prepared to ask and answer questions about the company s products and direction. You will probably have to shine during several interviews, from an initial telephone interview to a meeting with a trainer and an interview with at least one district manager. You may also be asked to accompany another sales rep on his rounds.

    According to the Salary Wizard, the national median salary for a pharmaceutical sales representative is around $56,000, not including bonuses.

    Running Your Own Show

    Once you ve landed your first job, you have to hit the ground running and excel in a profession that s for self-motivators. Pharmaceutical reps must be good at following up and deciding where to focus their time and efforts, Nahman says. In a typical day, a pharma sales reps makes several calls to hospitals, HMOs, doctors offices and pharmacies. Life in the field can be lonely. The biggest challenge is to be psyched up every day, he explains. If you re excited, that translates visually, and the doctors feed off that excitement. You have to have mental stamina to be just as fresh for that last call at 6 p.m. as you were for the first call at 8 a.m.

    Related Articles

    Glossary of Medicinal Chemistry #zydus #pharma

    #medicinal chemistry


    International Union of Pure and Applied Chemistry
    Chemistry and Human Health Division
    Medicinal Chemistry Section


    (IUPAC Recommendations 1998)

    Prepared for publication by C.G. Wermuth 1 (Chairman), C.R. Ganellin 2. P. Lindberg 3 and L.A. Mitscher 4

    1 Facult de Pharmacie, Universit Louis Pasteur, Strasbourg (France),
    2 University College London, London (U.K.)
    3 Astra H ssle AB, M lndal (Sweden)
    4 School of Pharmacy, University of Kansas, Lawrence (Kansas, USA)

    The definitions used in this glossary are identical to those in the published document, see Pure Appl. Chem.. 70. 1129-1143 (1998) [Copyright IUPAC; reproduced with the permission of IUPAC]. If you use any of these definitions please cite this reference as their source. For problems in converting the text into a World Wide Web version see the IUPAC home page.

    A PDF of the document is available.

    For Belorussian version see

    Abstract: The objective of the glossary is to provide in a single document a consistent terminology and concise definitions of terms covering the various aspects of medicinal chemistry. This was felt necessary with regard to the rapid changes occuring in medicinal chemistry and also by the need to establish international definition standards. Effectively the possibility exists that in different countries certain terms may not have the same meaning, in such a case the creation of an internationally accepted definition is particularly justified.

    A Working Party belonging to the IUPAC Section on Medicinal Chemistry has therefore been assembled which prepared the present glossary. Concise but sufficiently explanatory definitions have been formulated for about one hundred commonly employed terms which can be considered of particular interest to the medicinal chemistry community. The glossary has been compiled in part from definitions proposed by the Working Party in part from earlier IUPAC glossaries and in part from well-accepted definitions taken from the literature but which were sometimes published in journals or books that may not be readily accessible.


    The glossary has been compiled in part from definitions proposed by the Working Party and in part from well-accepted definitions taken from the literature. In most cases, definitions given here are for specific areas of medicinal chemistry. Some definitions taken from the Glossary for Chemists of Terms Used in Biotechnology (Pure Appl. Chem.. 1992. 64. 143-168; (c) 1992 IUPAC) were also included, eventually in a slightly modified form; they are identified by an asterisk*. Others, which appear in the Glossary on Computational Drug Design (Pure Appl. Chem.. 1997. 69. 1137-1152) and in Glossary for Chemists of terms used in Toxicology (Pure Appl. Chem. 1993. 65. 2003-2122), are identified by a double** and a triple*** asterisk respectively.

    Pharmaceutical company promises 1, 500 new jobs for Georgia – CBS46 News #shionogi #pharma

    #pharmaceutical company jobs


    Pharmaceutical company promises 1,500 new jobs for Georgia

    It s lunchtime at the Blue Willow Inn and business is booming. It hasn t always been this good. The restaurant fell into bankruptcy three years ago. But better times soon could be ahead when a pharmaceutical company opens up a manufacturing plant a few miles away which could bring in more than 1,500 new workers.

    Billie Van Dyke, who owns Blue Willow, hopes she gets her slice of the economic pie when Baxter International moves in. “That means my business is going to increase also,” Van Dyke said. “I m going to feed them.”

    This small city, 40 miles east of Atlanta, needs it. “For rent” and “closed” signs dot the businesses along the main strip, Cherokee Road. Baxter plans to invest more than $1 billion once it moves into a mixed use development, Stanton Springs, just off Interstate 20. Right now, it s little more than a long road to nowhere in the middle of an undeveloped field. But people who live and work nearby hope it ll drive the engine to economic recovery.

    Joel Clegg owns the ace hardware store. His business is half of what it was six years ago. More employees at Baxter could mean more customers filling the aisles at ace hardware. “It ll be real god for the community,” Clegg said. “Hopefully, that ll mean more people in the area buying up some of the homes and hopefully more customers.”

    Van Dyke said all the new business could help her out of a tough economy. “I think my business is going to double,” Van Dyke said.

    CBS Atlanta asked the State Department of Economic Development if the new development will cost the taxpayers anything. A spokeswoman said she ll call back with an answer.

    Copyright 2012WGCL-TV(Meredith Corporation). All rights reserved.

    Copyright 2000 – 2016 WorldNow and CBS46 News Atlanta

    Isis Pharma Ruboril 50 Expert Tinted Cream reviews, photos, ingredients #mcneil #pharma

    #isis pharma products


    Isis Pharma Ruboril 50+ Expert Tinted Cream

    Ruporil line is for redness and couperosis made in France. Got it from local pharmacy. Tint is very light beige colour, evens out redness but does not cover broken capillars entirely and dries into very matte finish. It needs some moisturizer under or it will stick to all dry patches. I still need serum and/ or moisturizer even though my skin is quite normal now when weather is colder, comb. in summer and I bought this after summer. I haven`t bothered to try it for whole face, only for nose where I have minor redness and those annoying broken caps on sides. I have used this for over a month now and I can`t see anything that my regular sc hasn`t allready done/ helped with redness. It is water resistant, fragrance free with golden chamomille extract, european patent and has parabens.
    This makes a great nose primer:). Some fndns still slide off/ fade away easily on sides of my nose and somehow this helps fndns stick and stay in place better than any other “real” face primer. And it does not break me out. Great, because otherwise I would have wasted 22euros/ 30 ml 🙂 Bit difficult to rate! Doesnt do its job but does another one.

    1 out of 1 people found this review helpful.

    Popular Treatments (Face)